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1.  INTRODUCTION 
 Oral solid dosage forms are the preferred routes for many drugs and are still 
the most widely used formulations for new and existing modified release products. 
The benefits offered by modified release systems include reducing dosing frequency 
with improved patient compliance, better and more uniform clinical effects with lower 
incidence of side effects and possible enhanced bio-availability. The rational design of 
modified release systems where, biological, physicochemical and physico-mechanical 
considerations have been taken into account during formulations of modified release 
dosage form, has alleviated the risk of dose dumping in vivo.1  
The success of therapy depends on selection of appropriate delivery systems 
as much as it depends on drug itself.2 Hence, in recent years pharmaceutical research 
considerably focussing on the Controlled release drug delivery systems as these have 
a number of advantages over conventional preparations. Controlled release drug 
delivery systems are designed to achieve a prolonged therapeutic effect by 
continuously releasing medication over an extended period of time after 
administration of a single dose.3  
1.1 MODIFIED RELEASE DELIVERY SYSTEMS4 
 The term modified – release defines preparations that have been designed in 
such a way that the rate (or) place at which the active ingredients are released has 
been modified.  
 Modified release delivery systems may be divided into 4 categories.  
A) Delayed release  
B) Sustained release  
(a) controlled release  
(b) extended release  
C) Site specific targeting  
D) Receptor targeting  
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A) Delayed release: 
 These systems are those that use repetitive, intermittent dosing of a drug from 
one or more immediate release units incorporated into a single dosage form. 
Examples of delayed release systems include repeat action tablets and capsules and 
enteric coated tablets where timed release is achieved by a barrier coating. They do 
not maintain uniform drug level in therapeutic range.  
B) Sustained release: 
 These systems include any drug delivery system that achieves slow release of 
drug over an extended period of time.  
 
a) Controlled release: 
 These systems provide continuous release of their active ingredients at a 
predetermined rate and for predetermined time, or in other words, a slow release of 
drug over an extended period of time and also can provide some control, whether this 
be of a temporal or spatial nature, or both, of drug release in the body. This system 
maintaining constant drug levels in target tissue or cells.   
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b) Extended release: 
Pharmaceutical dosage forms that release the drug slower than normal manner 
at predetermined rate and necessarily reduce the dosage frequency by two folds.  
C) Site specific targeting: 
These systems refer to targeting of a drug directly to a certain biological 
location. In this case the target is adjacent to or in the diseased organ or tissue.  
D) Receptor targeting: 
These systems refer to targeting of a drug directly to a certain biological 
location. In this case the target is the particular receptor for a drug within an organ or 
tissue.  
Site specific targeting and receptor targeting systems satisfy the spatial aspect 
of drug delivery and are also considered to be controlled drug delivery systems.  
1.2 ORAL CONTROLLED RELEASE SYSTEMS 5  
These systems release the drug for a prolonged period of time along the entire 
length of GIT with normal transit of the dosage form. The various systems under this 
category are,  
1. Dissolution controlled release systems.  
2. Diffusion controlled release systems.  
3. Dissolution and diffusion controlled release systems.  
4. Ion – exchange resin drug complexes.  
5. Slow dissolving salts and complexes.  
6. pH – dependent formulation.  
7. Osmotic pressure controlled systems.  
8. Hydrodynamic pressure controlled systems.  
1. Dissolution controlled release systems  
 Such systems are easiest to design. The techniques employed is  
1. Embedment is slowly dissolving or erodible matrix.  
2. Encapsulation or coating with slowly dissolving or erodible substances.  
INTRODUCTION 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai                                    4 
 
 
Matrix (or Monolith) Dissolution Controlled Systems: 
 Matrix systems are also called as monoliths, since the drug is homogenously 
dispersed throughout a rate – controlling medium. They are very common and employ 
waxes such as beeswax, carnauba wax, hydrogenated castor oil, etc which control 
drug dissolution by controlling the rate of dissolution of fluid penetration into the 
matrix by altering the porosity of the tablet, increasing its wettability or by itself 
getting dissolved at a slower rate. The wax embedded drug is generally prepared by 
dispersing the drug in molten wax and congealing and granulating the same. The drug 
release is often first order from such matrices.  
Encapsulation / coating dissolution controlled system (reservoir devices):  
 The drug particles are coated or encapsulated by one of the several 
microencapsulation techniques with slowly dissolving materials like cellulose, PEGs, 
polymethacrylates, waxes etc. The resulting pellets may be filled as such in hard 
gelatin capsules or compressed into tablets. The dissolution rate of coat depends upon 
the solubility and thickness of the coating which may range from 1-200 microns.  
2. Diffusion controlled release systems  
 The two types of diffusion controlled systems are matrix systems and reservoir 
devices. 
Matrix Diffusion Controlled Systems:  
 In this system, the drug is dispersed in an insoluble matrix of rigid 
nonswellable hydrophobic materials or swellable hydrophilic substances. Materials 
used for rigid matrix are insoluble plastics such as PVC and fatty materials like stearic 
acid, beeswax, etc. With plastic materials, the drug is generally kneaded with the 
solution of PVC in an organic solvent for granulation and compressed into tablets. 
Swellable matrix systems are popular for sustaining the release of highly water – 
soluble drugs. The materials used for such drugs are generally hydrophilic gums and 
may be of natural origin (guar gum, tragacanth), semi synthetic (HPMC, CMC, 
xanthan gum) or synthetic (polyacrylamides). The drug and gum are granulated 
together with a solvent such as alcohol and compressed into tablets. The release of 
drug from such initially dehydrated hydrogels involves simultaneous absorption of 
water (resulting in hydration, gelling and swelling of gum) and desorption of drug via 
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a swelling controlled diffusion mechanism. As the gum swells and the drug diffuses 
out of it, the swollen mass, devoid of drug appears transparent or glasslike and 
therefore the system is sometimes called as glassy hydrogel. The drug release follows 
Fickian first – order diffusion under equilibrium conditions. However during the 
swelling process, such equilibrium may not exist and the diffusion may be Non – 
Fickian or anomalous diffusion.  
Reservoir devices (or Laminated Matrix Devices):  
 These systems are hollow containing an inner core of drug surrounded by a 
water insoluble polymer membrane. The polymer can be applied by coating or 
microencapsulation techniques. The drug release mechanism across the membrane 
involves its partitioning into the membrane with subsequent release into the 
surrounding fluid by diffusion. The polymer commonly used in such devices are HPC, 
ethyl cellulose and poly vinyl acetate.  
3. Dissolution and diffusion controlled release systems:  
 In such systems, the drug core is encased in a partially soluble membrane. 
Pores are thus created due to dissolution of parts of the membrane which  
a. permit entry of aqueous medium into the core   
b. drug dissolution and allow diffusion of dissolved drug out of the system.  
An example of obtaining such a coating is using a mixture of ethyl cellulose 
with PVP or methyl cellulose the latter dissolves in water and create pores in the 
insoluble ethyl cellulose membrane.  
4. Ion – exchange resin drug complexes:  
 Controlled delivery of the acidic and basic drugs can be obtained by 
complexing them with the insoluble nontoxic anion exchange and cation exchange 
resins respectively. The drug is released slowly by diffusion through the resin particle 
structure. The following equation represents the release of a basic drug, NH2R, from a 
cation exchange resin RSO3H when in contact with GI fluid containing an ionic 
compound.  
−−+−−++− +→+ BRNHARSOBARNHRSO I33I33  
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 A number of basic drugs like phenylpropanolamine and pheniramine have 
been retarded by such an approach.  
5. Slow dissolving salts and complexes:  
 Salts or complexes of drugs which are slowly soluble in the GI fluids can be 
used for control release of the active principle. Amine drugs can be reacted with 
tannic acid to form poorly soluble complexes that can be formulated as long acting 
tablets. Penicillin G has been complexed with N,N – dibenzyl ethylenediamine to give 
benzathine penicillin G that can be formulated as oral suspension.  
6. pH – Independent formulation:  
 Such systems are designed to eliminate the influence or changing GI pH on 
dissolution and absorption of drug by formulating them with sufficient amount of 
buffering agent that adjust the pH to the desired value as the dosage form passes along 
the GIT and permit drug dissolution and release at a constant rate independent of GI 
pH. The dosage form containing drug and buffer is coated with a permeable substance 
that allows entry of aqueous medium but prevents dispersion of tablet.  
7. Osmotic pressure controlled systems:  
 It works on the principle of osmotic pressure to release the drug at a constant 
zero order rate. A core comprising of drug and an osmotically active substance such 
as potassium chloride or mannitol is surrounded by a rigid semipermeable membrane 
coating such as cellulose ester or cellulose ether having an orifice of 0.4mm diameter 
produced by laser beam for drug exit. When exposed to GI fluids, water flows through 
the semi permeable membrane into the tablet due to osmotic pressure difference 
which dissolves the drug and pumps it out through the orifice by the osmotic force. 
Such devices can be used to target specific areas of the GIT.  
8. Hydrodynamic pressure controlled systems:  
 The hydrodynamic pressure generating by swelling of a hydrophilic gum can 
also be used to achieve the delivery of drugs. The device comprises of a rigid, shape 
retaining housing enclosing a collapsible, impermeable compartment containing 
liquid drug. The space between the external housing and the drug compartment 
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contains a layer of swellable, hydrophilic gum such as polyhydroxyalkyl 
methacrylate. In the GIT, the gum imbibes water through the opening present at the 
lower side of external housing and swells creating a hydrodynamic pressure. The 
pressure thus created squeezes the collapsible drug reservoir to release the 
medicament through the delivery orifice at a zero order rate.  
1.3 HYDROPHILIC MATRIX SYSTEMS  
 A matrix is a uniform mixture of drug and excipients. For example, polymer 
that is homogenously mixed in solid dosage form. Oral sustained release dosage 
forms are commonly prepared by incorporating the drug into a hydrophilic polymer 
matrix. The hydrophilic matrix consist of a mixture of one more active ingredients 
with one or more gel forming agents. The mixture is usually compressed into tablets.6  
 The use of hydrophilic matrices has become extremely popular in controlling 
the release of drugs from solid dosage forms.7 
 Various types of polymers used as hydrophilic matrices. The most commonly 
used cellulose ethers are hydroxypropyl methyl cellulose (HPMC), hydroxy propyl 
cellulose, sodium carboxy methyl cellulose (SCMC), and methyl cellulose. This 
popularity system from their non toxic nature, case of compression, ability to 
accomodate a large percent of drug and negligible influence of the processing 
variables on drug release rates.8  
 For matrix devices, drug is often release by diffusion process such that a 
receding drug boundary will exist within the device.9  
Mechanism of Release:10 
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The two important parameters for the release of drug from tablet matrices are 
• The infiltration rate of medium into the matrix (absorption rate) for which the 
drugs with aqueous solubility. 
• The erosion rate of the matrix system for which the drugs with poor aqueous 
solubility. 
The release rate of poorly soluble drug can be controlled by the rate of tablet erosion. 
The tablet erosion rate can also be adjusted by the choice of HPMC polymer viscosity 
or by mixing HPMC of different viscosity grades. 
(A) Water penetration, swelling of matrix and Gel layer formation Dynamics: 
 Swellable matrix tablets are activated by water and drug release control 
depends on the interaction between water, polymer and drug. Water penetration into 
the matrix is the first step leading to polymer swelling and drug dissolution. The 
presence of water decreases the glassy-rubbery temperature (eg, for HPMC from 
184oC to lower than 37oC) giving rise to the transformation of glassy polymer in a 
rubbery phase (gel layer). The enhanced mobility of the polymeric chains favours the 
transport of dissolved drug. Polymer relaxation phenomena determine the swelling or 
volume increase of the matrix. The later may add a convective contribution to the 
drug transport mechanism in drug delivery.11 
 Drug release kinetics is strictly associated with the dynamics of the gel layer. 
It ranges Fickian to anomalous (Non fickian), and subsequently from quasi-constant  
to constant, becoming first order at the end. Due to the insufficient polymeric mass 
transfer due to a low chain disentanglement rate, HPMC swellable matrices rarely 
show all three described regimens during the drug release time.12 
(B) Boundaries of Gel layer and relevant Fronts: 
 Gel layer thickness is defined by the front separating the matrix from the 
dissolution medium, i.e., the erosion front, and by the front separating the glassy from 
the rubbery polymer (i.e., the swelling front). Therefore, erosion and swelling front 
movements are the controllers of gel layer behavior. 13 
The presence of a third front inside the gel layer was described by swellable 
matrices containing Diclofenac, as the consequence of precipitation in gel layer of this 
poorly soluble drug already molecularly dispersed in the glassy matrix. This front, 
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named diffusion front, corresponds to the boundary between undissolved and 
dissolved drug. It was further shown that, depending on the function of drug solubility 
and loading, its presence is highly probable in swellable matrix tablets.14 Therefore, in 
swellable matrix tablets conditions exist under which the following three fronts can be 
present at the same time. 
1.4 CONTROLLED DRUG DELIVERY SYSTEM 
Controlled drug delivery occurs when a polymer, whether natural or synthetic, 
is judiciously combined with a drug or other active agent in such a way that the active 
agent is released from the material in a predesigned manner. The release of the active 
agent may be constant over a long period, it may be cyclic over a long period, or it 
may be triggered by the environment or other external events. The goal of many of the 
original controlled-release systems was to achieve a delivery profile that would yield 
a high blood level of the drug over a long period of time. In controlled drug delivery 
systems designed for long-term administration, the drug level in the blood follows the 
profile remaining constant, between the desired maximum and minimum, for an 
extended period of time. Depending on the formulation and the application, this time 
may be anywhere from 24 hours (Procardia XL) to 1 month (Lupron Depot) to 5 years 
(Norplant).16 
ADVANTAGES OF CONTROLLED DRUG DELIVERY SYSTEM: 
• The purpose behind controlling the drug delivery is to achieve more effective 
therapies while eliminating the potential for both under- and overdosing. 
• Using controlled-delivery systems can include the maintenance of drug levels 
within a desired range, the need for fewer administrations, optimal use of the drug 
in question, and increased patient compliance.16 
• Reduction in fluctuation in steady state levels and therefore better control of 
disease condition and reduced intensity of local or systemic side effects. 
• Increased safety margin of high potency drugs due to better control of plasma 
levels. 
• Oral modified/controlled release delivery systems offer a number of advantages 
including improvement in patient compliance, greater selectivity of 
pharmacological activity, therapeutic efficiency and safety, decreased side effects, 
and reduced dosing frequency. 
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DISADVANTAGES OF CONTROLLED RELEASE DOSAGE FORMS: 
• The possible toxicity or non biocompatibility of the materials used, undesirable 
by-products of degradation, any surgery required to implant or remove the system, 
the chance of patient discomfort from the delivery device. 
• The higher cost of controlled-release systems compared with traditional 
pharmaceutical formulations. 
• Burst effect: In case of many controlled release formulations, upon placement in 
the release medium, there is an immediate release of an initial large bolus of drug 
is released before the release rate reaches a stable profile. This phenomenon is 
typically referred to as 'burst release'.  
• First order release kinetics  
• Increase in metabolic rate: This leads to higher initial drug delivery and also 
reduces the effective lifetime of the device.  
• Increase in dosing frequency etc. 
1.5 DIFFERENT ROUTES OF THE CONTROLLED RELEASE DRUG 
DELIVERY SYSTEMS:17 
 The different route of controlled release drug delivery systems as follows, 
• Oral 
• Transdermal 
• Parenteral 
• Ophthalmic 
• Intravaginal and intrauterine 
 The development of controlled-release formulations continues to be a big 
success for the pharmaceutical industry. The success of any technology relies on the 
ease of its manufacturing process and its reproducibility of desirable 
biopharmaceutical properties. 
 Amongst all of the above controlled drug delivery systems, oral controlled 
release delivery has received major attention because of its greater popularity, and it 
provide a uniform concentration/amount of drug at the absorption site and thus after 
absorption, allow maintaince of plasma concentration with in therapeutic range, which 
minimizes side effects and also reduces the frequency of administration.19 
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“Oral controlled drug delivery systems are those that provide continuous oral 
delivery of drugs at predictable and reproducible kinetics, for a predetermined period 
throughout the course of GI transit.17 
Advantages of oral route for drug delivery: 
• Patient acceptability and compliance. 
• Therapeutic advantage 
• Reduction in adverse side effects and improvement in tolerability 
• Reduction in healthcare cost 
• Ideally, oral controlled-release systems are reliant upon the dosage form to control 
the rate of drug release with little or no effect from the intrinsic properties of the 
drug or the conditions prevailing within the gastro intestinal (GI) tract. 
• Large surface area of small intestine 
• High vascular surface of gastrointestinal mucosa. 
• Zero order controlled release 
• Commercial advantages: The cost of oral therapy is generally much lower in 
comparison to parenteral and other routes of drug delivery.17 
Disadvantages: 
• Lack of in vitro–in vivo correlation. 
• Variability 
• Adverse environmental effects: high metabolic activity, extreme of pH, intestinal 
motility, mucus barrier, P-glycoprotein efflux pump, Impermeable epithelium. 
Several terms have been used to describe the various types and modes of action, 
intended to provide long duration of drug activity. These are 
CONTROLLED RELEASE PREPARATIONS 
 Although this term has been interchanged widely with sustained release 
preparations in the past, recently it has become customary to restrict the latter term to 
oral formulations where the mechanism of prolonged action is dependent on one or 
more of the environmental factors in the gastrointestinal tract such as pH, enzymes, 
gastric motility etc. On the other hand, the term controlled release dosage form 
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usually applies to preparations that are designed for all routes of administration and 
where the mechanism of prolonged action is inherent and determined totally by the 
delivery system itself. Consequently, this category offers the current state-of-the-art 
products where the drug release profile is controlled accurately and often can be 
targeted to a special body site or a particular organ. 
1.6 CLASSIFICATION OF ORAL CONTROLLED DRUG DELIVERY 
SYSTEMS18 
TYPE OF SYSTEM     RATE-CONTROL MECHANISM 
Dissolution controlled 
Monolithic devices    Dissolution of the matrix 
Reservoir devices    Dissolution of encapsulation and coating 
Diffusion Controlled 
Monolithic devices    Diffusion through membrane  
Reservoir devices     Diffusion through bulk polymer 
Water Penetration Controlled 
            Osmotic systems  Osmotic transport of water through 
semipermeable membrane, Swelling 
systems  
Water penetration into glassy Polymer. 
Hydrodynamic pressure systems Water absorption through the annular 
openings into hydrophilic polymer 
pH controlled gastrointestinal drug Dissolution of drug at appropriate 
constant 
delivery systems pH by water permeation into the device. 
Chemically Controlled 
Monolithic systems Either pure polymer erosion (surface 
erosion) or combination of erosion and 
diffusion (bulk erosion) 
Pendant chain systems Combination of hydrolysis of pendant 
group and diffusion from bulk polymer  
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Ion exchange controlled Combination of biodegradation of drug 
bound resin, diffusion through the 
membrane and exchange of ions.   
Gastrointestinal retention controlled  
Mucoadhesives Prolonging the residence time of dosage 
form in the GI tract.  
Altered density formulations  
High density approach  Increased density of pellets than that of 
stomach content 
Low density approach Maintaining buoayancy of the device. 
1.7 GASTRO INTESTINAL RETENTION CONTROLLED DRUG DELIVERY 
SYSTEM20: 
Among the different type of formulation, gastric emptying8 of dosage forms is 
an extremely variable process and ability to prolong and control the emptying time is 
a valuable asset for dosage forms, which reside in the stomach for a longer period of 
time than conventional dosage forms. Several difficulties are faced in designing 
controlled release systems for better absorption and enhanced bioavailability. One of 
such difficulties is the inability to confine the dosage form in the desired area of the 
gastrointestinal tract.  
Gastro Retentive drug delivery systems can be retained in the stomach for a 
long time. Such retention systems are important for drugs that are degraded in 
intestine or for drugs like antacids or certain antibiotics. The main objective of 
developing these systems is to increase the safety of a product, to extend its duration 
of action and decrease the side effects of drugs. 
Factors Affecting Gastric Retention 20 
 There are several factors that can affect gastric emptying (and hence GRT) of 
an oral dosage form. These factors include: 
• Density of the dosage form: A dosage form having a density of less than that 
of the gastric fluids floats. 
• Size of the dosage form: Small-sized tablets leave the stomach during the 
digestive phase while the large-sized tablets are emptied during the 
INTRODUCTION 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai                                    14 
 
 
housekeeping waves. Dosage forms having a diameter of more than 7.5 mm 
show a better gastric residence time compared with one having 9.9 mm. 
• Shape of the dosage form: It is reported that tetrahedron and ring-shaped 
devices have a better gastric residence time as compared with other shapes. 
• Gender: Generally females have slower gastric emptying rates than males. 
• Posture: When subjects were kept in the supine position it was observed that 
the floating forms could only prolong their stay because of their size; 
otherwise the buoyancy remained no longer an advantage for gastric retention.  
• Temperature of meal: Cold meal increases and hot meal decreases the 
emptying of gastric contents.  
• Composition and Viscosity of meal: Fats, particularly fatty acids inhibit 
gastric secretion and have a pronounced reductive effect on the rate of 
emptying. Proteins and starch are shown to have inhibitory effect on gastric 
emptying, though to a less extent. As the viscosity of the gastric fluids is 
increased, there is a corresponding decrease in the rate of emptying. 
• Volume: As the volume of liquid present in the gastric pouch increases, the 
rate of gastric emptying decreases. 
• Increase in acidity of the duodenal contents slow down gastric emptying time.  
• Diseased states: Gastric emptying is affected in diseased conditions like 
diabetes, Crohn’s disease, etc. 
 
Approaches to Design Gastro Retentive Dosage Forms 22 
 Over the years, various approaches have been pursued to increase the retention 
of an oral dosage form in the stomach. Gastro retentive systems remain in the gastric 
region for several hours and hence significantly prolong the gastric residence time of 
drugs. These may be: 
 Floating Drug Delivery Systems (FDDS) or Hydrodynamically Balanced 
Systems (HBS) : These are systems which have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach without affecting the 
gastric emptying rate for a prolonged period of time. While the system is 
floating on the gastric contents, the drug is released slowly at a desired rate 
from the system. 
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 Swelling and Expanding Drug Delivery Systems: These types of dosage forms 
are such that after swallowing, these products swell to an extent that prevents 
their exit from the stomach through the pylorus. As a result, the dosage form is 
retained in the stomach for a long period of time. These systems may be 
referred to as ‘plug type systems’ since they exhibit a tendency to remain 
lodged at the pyloric sphincter. 
 Bioadhesive Systems : These systems are used to localize a delivery device 
within the lumen and cavity of the body to enhance the drug absorption 
process in a site-specific manner. The approach involves the use of 
bioadhesive polymers that can adhere to the epithelial surface of the GI tract. 
The proposed mechanism of bioadhesion is the formation of hydrogen and 
electrostatic bonding at the mucus-polymer boundary. Rapid hydration in 
contact with the muco-epithelial surface appears to favor adhesion, 
particularly if water can be excluded at the reactive surfaces. 
 Modified Shape Systems : These systems are non disintegrating geometric 
shapes molded from silastic elastomer or extruded from polyethylene blends, 
which extend the GRT depending on size, shape and flexural modulus of the 
drug delivery device. 
 High Density Systems : These formulations include coated pellets, which have 
a density greater than that of the stomach contents (approx. 1.004 g/ cm3 ). 
This is accomplished by coating the drug with a heavy inert material such as 
barium sulfate, zinc oxide, titanium dioxide, iron powder, etc. 
 Delayed gastric emptying systems : These approaches of interest include sham 
feeding of indigestible polymers or fatty acid salts that change the motility 
pattern of the stomach to a fed state, thereby decreasing the gastric emptying 
rate and permitting considerable prolongation of drug release. 
1.8 Classification of Floating Drug Delivery Systems (FDDS) 21 
 Based on the mechanism of buoyancy, FDDS are classified into two distinctly 
different technologies, i.e., Non-effervescent and Effervescent systems 
A) Non-Effervescent Floating Dosage Forms 
Non-effervescent floating dosage forms use a gel forming or swellable 
cellulose type of hydrocolloids, polysaccharides, and matrix-forming polymers like 
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polycarbonate, polyacrylate, polymethacrylate, and polystyrene. The formulation 
method includes a simple approach of thoroughly mixing the drug and the gel-
forming hydrocolloid. After oral administration this dosage form swells in contact 
with gastric fluids and attains a bulk density of less than 1. The air entrapped within 
the swollen matrix imparts buoyancy to the dosage form. The so formed swollen gel-
like structure acts as a reservoir and allows sustained release of drug through the 
gelatinous mass. 
 
B) Effervescent Floating Dosage Forms 
These are matrix types of systems prepared with the help of swellable 
polymers such as methylcellulose and chitosan and various effervescent compounds, 
e.g., sodium bicarbonate, tartaric acid, and citric acid. They are formulated in such a 
way that when in contact with the acidic gastric contents, CO2 is liberated and gets 
entrapped in swollen hydrocolloids, which provides buoyancy to the dosage forms. 
 
Advantages of Floating Drug Delivery Systems 22 
9 Sustained Drug Delivery 
These systems can remain in the stomach for long periods and hence can release 
the drug over a prolonged period of time. The problem of short gastric residence 
time, encountered with an oral CR formulation can hence be overcome with these 
systems. These systems have a bulk density of <1, as a result of which they can 
float on the gastric contents.  
9 Site-Specific Drug Delivery 
These systems are particularly advantageous for drugs that are specifically 
absorbed from stomach or the proximal part of the small intestine. eg., Riboflavin, 
Furosemide, Ciprofloxacin, etc.  
9 Absorption Enhancement 
Drugs that have poor bioavailability because of site-specific absorption from the 
upper part of the gastrointestinal tract are potential candidates to be formulated as 
floating drug delivery systems, thereby maximizing their absorption. 
9 Complete eradication of Helicobacter pylori in peptic ulcer can be achieved only 
by floating drug delivery systems. 
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Limitations of Floating Drug Delivery Systems 22 
o They require a sufficiently high level of fluids in the stomach for the drug delivery 
system to float therein and to work efficiently. However, this limitation can be 
overcome by coating the dosage form with bioadhesive polymers, thereby 
enabling them to adhere to the mucous lining of the stomach wall. Alternatively, 
the dosage form may be administered with a glass full of water (200–250 ml). 
o Floating systems are not feasible for those drugs that have solubility or stability 
problems in gastric fluids. E.g., Drugs such as nifedipine. Also there are 
limitations to the applicability of FDDS for drugs that are irritant to gastric 
mucosa and those drugs which have multiple absorption sites in the Gastro 
Intestinal Tract. 
o These systems, being matrix formulation, consists of a blend of drug and low 
density polymers. The release kinetics of drug cannot be changed without 
changing the floating properties of the dosage form and vice versa. 
Evaluation 22 
 Gastroretention of the systems can be evaluated by X-ray or γ-scintigraphy. 
Modern technique of γ-scintigraphy now makes it possible to follow the transit 
behaviour of dosage form in human volunteers in a non-invasive manner. 
Marketed Floating Formulations 23 
• Valrelease®          - diazepam (Hoffmann La-Roche,USA) 
• Madopar®                    -   benserazide and L-dopa (Roche, USA) 
• Liquid gaviscon®  -   floating liquid alginate preparation(GSK,india) 
• Topalkan®         -Alginate Al-Mg antacid preparation(pierre fabre 
 drug,france) 
• Cytotech®                   - Misoprostol floating capsule (pharmacia, USA) 
 The currently available polymer-mediated non-effervescent and effervescent 
FDDS, designed on the basis of delayed gastric emptying and buoyancy principles, 
appear to be an effective and rational approach to the modulation of controlled oral 
drug delivery. This is evident from the number of commercial products and a myriad 
of patents issued in this field. 
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2. LITERATURE REVIEW 
2.1 LITERATURE REVIEW ON GASTRO RETENTIVE FLOATING TABLET: 
Shishu24 et al., (2007) formulated gastro-retentive floating tablets for 5-
fluorouracil (5-FU) to prolong the gastric residence time, increase drug bioavailability 
and target the stomach cancer. This floating tablet consists of gas-forming agents, like 
sodium bicarbonate, citric acid and hydrocolloids, like hydroxypropyl methylcellulose 
(HPMC) and carbopol 934P. The in-vitro release studies showed that the optimized 
formulation could sustain drug release for 24 h and remain buoyant for 16 h.  
Denish Kalaria25 et al., (2011) formulated the gastro-retentive floating tablets of 
acyclovir to prolong the gastric residence time after oral administration, at a particular 
site and controlling the release of drug, which results in achieving controlled plasma level 
as well as improving bioavailability. Compression of tablets by wet granulation with 
incorporation of gas-generating agent together with polymer HPMC improved drug 
release and optimal floating (floating lag time ~30 s; total floating time >12 h). The drug 
release was sufficiently sustained (more than 11h) and non-Fickian as well as zero-order 
was confirmed. 
Gangadharappa H.V26 et al., (2011) prepared gastric floating tablets of atenolol 
consists of karaya gum and HPMC as matrix polymers, sodium bicarbonate as a gas-
generating agent, which undergoes direct compression technique. The optimized 
formulation had shown good floating capability, shorter floating lag time, and sustained 
drug release for 12 h. The in-vitro drug release followed different models like korsmeyer-
peppas, and huguchi. The diffusion exponent ranges from 0.3771 to 0.6997 indicating the 
Fickian and anomalous transport.  
Lingam Meka27 et al., (2008) formulated captopril matrix type multiple-unit 
gastro- retentive floating tablet. The drug containing core units prepared by direct 
compression process, which are coated with three successive layers of an inner seal coat, 
effervescent layer (sodium bicarbonate) and an outer gas-entrapped polymeric membrane 
of an polymethacrylates (Eudragit RL30D, RS30D, and combinations of them). The 
optimized system completely floated within    3 min and maintained the buoyancy over a 
period of 12 h.  
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R. K. Kar28 et al., (2010) prepared Cefuroxime Axetil gastro retentive floating 
tablets hydrophilic polymers such as HPMC K15M and HPMC E5LV were used for its 
release controlling properties and sodium bicarbonate as gas generating agent and 
Sodium Lauryl Sulfate (SLS) was used as solubility enhancer. It was found that polymer 
content and amount of floating agent significantly affected 50% drug release (T50%), 
Mean dissolution time (MDT), release rate constant, and diffusion exponent (n).Kinetic 
modeling of dissolution profiles revealed that the drug release mechanism could range 
from diffusion controlled to case II transport, which was co dominated by both diffusion 
polymer erosion in the release mechanism. 
Ajay Bagherwal29 et al., (2010) developed floating tablet of ciprofloxacin HCl 
by direct compression techniques using HPMC and carbomer in different proportion (4%, 
8% and 12%) polymers, lactose, magnesium stearate, talc with sodium bicarbonate. All 
the prepared formulation were found to comply with the official tests like precompression 
parameter like angle of repose and post compression parameters like floating test, content 
uniformity and in-vitro dissolution study. The mechanism of drug release with all the 
formulations was dominantly diffusion and followed zero order kinetics.  
Margret Chandira30 et al., (2009) studied the formulation of Diltiazem HCl 
floating tablets by direct compression technique using hydrophilic polymer like HPMC 
K4M, HPMC K15M and hydrophobic polymer like ethylcellulose as matrix materials in 
various quantities (%w/w), sodium bicarbonate, citric acid, magnesium stearate, talc and 
lactose in varying ratio to formulate the floating tablets. It was observed that tablets of 
optimized formulation showed greater extent of drug release and it was found to be 
around 99.81 % at the desired time 12 h. 
D.Bhowmik31 et al., (2009) studied poor bioavailability anti-ulcer drugs as 
Famotidine. Famotidine floating tablets formulated by direct compression technique 
using polymers like HPMC K4M and HPMC K100M, xanthan gum. The HPMC polymer 
alone release > 90% drug in 4-6 h itself, while in combination with xanthan gum it 
release > 90% drug upon 8 h. The result indicates that gas powered gastro-retentive 
floating tablets of famotidine containing HPMC K100M and Xanthan gum provides a 
better option for controlled release action and improved bioavailability. 
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Y.S.Tanwar32 et al., (2007) prepared Famotidine floating tablets incorporating 
two different grades of methocel K100 and methocel K15M, sodium bicarbonate. The 
floating tablets were evaluated for drug content, in-vitro buoyancy and dissolution 
studies. The tablet swelled radially and axially during invitro buoyancy studies. A 
combination of sodium bicarbonate (130mg) and citric acid (10mg) was found to achieve 
optimum invitro buoyancy. The tablets with methocel K100 were found to float for 
longer duration as compared with formulations containing methocel K15M. The drug 
release from the tablets was sufficiently sustained and non-Fickian transport of the drug 
from tablets was confirmed. 
Ravi Kumar33 et al., (2009) developed Floating drug delivery system (FDDS) for 
famotidine gas-forming agents like sodium bicarbonate, citric acid and hydrocolloids like 
hydroxypropyl methylcellulose (HPMC) and carbopol 934P to prolong the gastric 
residence time, increase drug bioavailability and target the gastric ulcer. The formulations 
were optimized for the different viscosity grades of HPMC, carbopol 934P and its 
concentrations and combinations. The results of the in-vitro release studies showed that 
the optimized formulation could sustain drug release (98%) for 24 h and remain buoyant 
for 24 h. 
Vishal G. Karkhile34 et al., (2010) formulated furosemide floating tablet using        
PEG- 6000 is used as complexing agent for increasing solubility of Furosemide in water, 
Hydroxy propyl methylcellulose, sodium bicarbonate and carbapol were used as 
matrixing agent, gas generating agent and floating enhancers respectively. The tablets 
were evaluated for in-vitro buoyancy and dissolution studies for 8 h. The data of in-vitro 
dissolution study shows that the zero order plots were found to be fairly linear as 
indicated by their high regression value (R2=0.9772 to 0.9911).  
Patel Krunal M35 et al., (2010) prepared gastro retentive floating tablets of 
Lansoprazole consists of chitosan, HPMC of different viscosity, sodium bicarbonate; 
citric acid and stearic acid were used. The formulation containing HPMC K4M show 
more retardation of drug release from the tablet. Hence to improve the drug release the 
quantity of HPMC K4M was reduced and chitosan was incorporated in the formulation. 
After the addition of chitosan the swelling index was increased as well as the drug release 
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and the floating time was also improved. Finally optimized floating lansoprazole tablet 
was formulated using two polymer i.e. chitosan and HPMC K4M. 
Arunachalam.A36 et al., (2010) prepared floating tablet of levofloxacin 
hemihydrates tablets by melt granulation method, using the polymer hydroxypropyl 
methyl cellulose (HPMC K100M) with different amounts, sodium bicarbonate as gas 
generating agent and other excipients. Tablets were evaluated by different parameters 
such as in-vitro release studies; Buoyancy determination and kinetic analysis of 
dissolution data etc., Levofloxacin floating tablet drug delivery system improved the oral 
bioavailability and extended drug release which may favor the reduced dose frequency 
and patient compliance. 
Ganesh Rajput37 et al., (2009) developed Metformin HCl gastro retentive tablets 
by directly compressible method using polymers HPMC K100M and HPMC K4M. It was 
concluded that polymer viscosity had major influence on drug release from hydrophilic 
matrix tablets as well as on floating lag time. When polymer viscosity increase the 
similarity factor f2 was increased. Hence, it concluded that the polymer viscosity affected 
the similarity factor f2. The different ratios of HPMC K4M and HPMC K100M were 
evaluated to achieve apparent viscosity to 66633 cps. The optimized batch showed the 
highest f2=82 value, it contained 37.34mg of HPMC K4M and 212.66mg of HPMC 
K100M. 
Laxmi Goswami38 et al., (2011) studied combined floating bilayer tablet of 
metformin and pioglitazone used as an oral hypoglycemic agent for control of diabetes. 
The fabrication of bilayer floating tablet was done by modified direct compression using 
polymer like HPMC, carbopol, PVP to facilitate immediate release of pioglitazone and 
sustained release of metformin. The formulated tablets were subjected to various 
evaluation parameters including buoyancy studies, drug content, in-vitro dissolution 
studies etc,. The formulated tablets remain buoyant over a period of 12-20 h and released 
more than 80% of drug in study period. 
Rajan B Mistry39 et al., (2011) formulated floating drug delivery system of 
clarithromycin containing drug, hydroxyl propyl methylcellulose (HPMC), sodium 
bicarbonate (gas generating agent) and different additives were compressed using wet 
granulation to prolong the gastric residence time after oral administration. The optimized 
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formulation was obtained using 150mg of HPMC K4M gave floating lag time less than 
30 sec and prolonged 82.56% of drug release  up to 6 h. 
Krunal Patel40 et al., (2011) prepared gastro retentive floating tablets of 
mebendazole consists of chitosan, HPMC of different viscosity, sodium bicarbonate; 
citric acid and stearic acid were used. The formulation containing HPMC K4M showed 
more retardation of drug release from the tablet. Hence to improve the drug release the 
quantity of HPMC K4M was reduced and chitosan was incorporated in the formulation. 
After the addition of chitosan the swelling index was increased as well as the drug release 
and the floating time was also improved. Finally optimized formulation was formulated 
using two polymer i.e. chitosan and HPMC K4M. 
Dalavi V.V41 et al., (2009) developed a gastro-retentive tablet of Zidovudine to 
enhance its bioavailability and sustained action. In 32 factorial design, amount of HPMC 
K4M (X1) and gas generating agents (X2) were selected as independent variable. The 
time required for 50% drug release t50% (Y1) was selected as dependent variable. The 
derived polynomial equations for t50%were verified by two check point formulations. 
The results of factorial design showed that factor X1 and X2 significantly affect the 
studied dependent variables. The formulation with good floating time (24hrs) and the 
percent drug release (98.05) emerged as optimal. 
MD. Selim Reza42 et al., (2009) formulated floating tablet of theophylline using 
two hydrophilic cellulose derivatives as Methocel K100M and Methocel K15MCR for 
their gel forming and release controlling properties, Sodium bicarbonate and citric acid as 
gas generating agents by direct compression technique. Formulations were evaluated for 
in-vitro buoyancy and drug release study was evaluated for 8 h. The release mechanisms 
were explored and explained with zero order, first order, Higuchi and Korsmeyer 
equations. It was found that polymer content and amount of floating agent significantly 
affected the mean dissolution time, percentage drug release after 8 h, release rate constant 
and diffusion exponent. 
Debajyothi Ray43 et al., (2010) developed floating tablet of tramadol HCl using 
different grades of HPMC as drug release retarding polymer and sodium bicarbonate as 
gas generating agent helps tablets to float. From the swelling study of the formulations, 
optimized formulation was found to be had good swelling properties (220%). The 
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optimized formulation was found to have better drug release profile than other 
formulations. From the drug release kinetic study, Higuchi model was found to be best 
fit. So it could be predicted that release of tramadol HCl from the floating drug delivery 
formulations were of diffusion type.  
N. Damodharan44 et al., (2009) formulated bi-layered floating tablets of 
theophylline by wet granulation technique. Bilayer tablets formulated with an 
immediately releasing layer consisting of theophylline with lactose as diluents and 
sustained release layer with slow releasing swellable matrix consisting of theophylline 
with different polymer ratios. The optimized formulation has a combination of hydroxy 
propyl methyl cellulose and methyl cellulose provide slow release of theophylline over a 
period of 9 h and were found suitable for maintenance portion of bilayered floating 
tablets. Theophylline release from these tablets was diffusion controlled and followed 
first order kinetics. 
  Kannan C45 et al., (2010) studied gastro-retentive rosiglitazone maleate floating 
tablets with various materials like hydroxy propyl methyl cellulose (HPMC) K4, K15, 
K100 were used for its gel forming and release controlling properties, sodium 
bicarbonate act as a effervescent agent and hydrophobic meltable material like bees wax 
formulated by melt granulation technique. The formulation F7 containing HPMC K15M 
and K100M shows sustained release profile and releases upto 12 h and it shows good 
buoyancy and total floating time. Floating tablets with sustained release characteristics 
offer critical advantages such as, site specificity with improved absorption and efficacy. 
Girish S. Sonar46 et al., (2007) developed a bilayer and floating-bioadhesive 
drug delivery system to prolong residence in the stomach. The sustained layer was 
compressed and granules of the floating layer were added to it, then both layers were 
compressed using a single station rotary press. Hydroxy propyl methylcellulose (HPMC) 
and sodium bicarbonate were added to the floating layer. The in-vitro drug release from 
the tablet was controlled by the amount of HPMC in the sustained release layer and it 
also affects the buoyancy lag-time, detachment force and swelling characteristics of the 
tablets. The release of rosiglitazone maleate from the tablets followed the matrix first-
order release model.  
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Puneeth K P47 et al., (2010) formulated rosigliazone maleate floating tablets 
using gas forming agents like sodium bicarbonate, tartaric acid and polymers like HPMC 
K15M and Xanthan gum. The prepared tablets were evaluated in terms of their 
precompression parameters, physical characteristics, in-vitro release, buoyancy and 
buoyancy lag time. The results of in-vitro release studies showed that optimized 
formulation could sustain drug release (98%) for 12h and remain buoyant for 12h. The 
optimized formulation was subjected to various kinetic release investigations and it was 
found that the mechanism of drug release was predominantly diffusion with a minor 
contribution from polymeric relaxation. 
Chander Shekar B48 et al., (2010) prepared floating tablets by direct 
compression technology consists of HPMC K100LV, HPMC K15M, ethyl Cellulose and 
effervescent sodium bicarbonate. The tablet swelled radically and axially during in vitro 
buoyancy studies. Final formulation released approximately 89.21% drug in 24 h in-vitro, 
while the floating lag time was not more than 35 Sec and the tablet remained floatable 
throughout all studies. The release of Ketoconazole was found to follow a mixed pattern 
of Korsmeyer-Peppas, Hixson-Crowell and zero order release models. The drug release 
from the tablets was sufficiently sustained and non-Fickian transport of the drug from 
tablets was confirmed. 
Prashant Khemariya49 et al., (2010) prepared ofloxacin floating tablets by dry 
granulation technique which containing HPMC K100M, xanthan gum, carbopol 934P, 
PVP K30, MCC, lactose, aerosil, and gas generating agent such as sodium bicarbonate 
were taken as independent variables. The in-vitro studies of optimized formulation 
released more than 80% drug in 10 h and remained buoyant for more than 24 h. The 
optimized formulation showed zero order release kinetics with a floating lag time of only 
2.9 mins. 
D. Saravanan50 et al., (2010) formulated ofloxacin floating tablet by wet 
granulation technique using HPMC K4M, HPMC K15M and HPMC K100M as polymers 
along with sodium bicarbonate as gas generating agent. All the formulations had 
undergone pre-compression and post-compression parameters. The in-vitro cumulative % 
drug release of the formulations F1A, F1B, F2A, F2B, F3A and F3B were 102.85%, 
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101.32%, 100.2%, 99.98%, 99.28% and 97.25% for 12 h and remained buoyant 
throughout the study. 
A. Kotwal51 et al., (2011) developed intra-gastric buoyant tablets of amoxicillin 
trihydrate using HPMC K15M and HPMC K100 as gelling agents, sodium bicarbonate as 
gas-generating agent and other excipients had undergone wet granulation technique and 
compressed into tablets. The in-vitro release studies indicated that the floating dosage 
form containing higher concentration of HPMC K100M showed slower release as 85.2% 
for 10 h. The in-vitro release data was treated with mathematical equations, and it was 
concluded that Amoxicillin released from the tablet followed Peppas model with non-
Fickian diffusion. 
V.Narayan52 et al., (2010) formulated floating gastro-retentive tablets of 
salbutamol sulphate (a short acting bronchodilators which have short biological half life 
about 2 - 4 h) by using swelling polymer like Methylcellulose, Hydroxy propyl methyl 
cellulose (K100M, K4M) in different concentration as 25, 50, 75 % w/w. The optimized 
formula consists of HPMC K100M at 50% and stearic acid 25%. The formulations, 
which have stearic acid retards the drug release by controlling the water penetrations in to 
the floating matrix tablets, sustained their drug release above 12 h. 
S.Ramkanth53 et al., (2010) formulated Diltiazem floating tablets with different 
concentrations of two grades of HPMC polymers (HPMC K4M and HPMC K100M) by 
using wet granulation technique and evaluated for the different evaluation parameters 
such as drug content uniformity, floating lag time, in-vitro buoyancy, in-vitro drug 
release studies were performed. The optimized formulation containing 25% HPMC K4M 
was found to release a maximum of 99.6% at the 12th hour. The drug release from 
optimized formulaiton was found to follow zero order kinetics. It was also found linear in 
Higuchi’s plot, which confirms that diffusion is one of the mechanisms of drug release. 
Anuradha K. Salunkhe54 et al., (2011) prepared floating pulsatile delivery 
system consisted of three different parts: a core tablet, containing the active ingredient, an 
erodible outer shell and a top cover buoyant layer. The rapid release core tablet (RRCT) 
was prepared by using super-disintegrants along with active ingredient. Dry coating of 
optimized RRCT was done by using different grades of hydroxy propyl methyl cellulose 
(HPMC) E5, E15, and E50 and upper most buoyant layer was prepared with HPMC 
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K15M and sodium bicarbonate. Developed formulations were evaluated for their drug 
content, in-vitro drug release profile (lag time), buoyancy studies and in-vivo X-ray 
study. The optimized formulation showed floating lag time of 4 min, floating time of 12 h 
and release lag time of 6 h.  
Balkrushna K. Patel55 et al., (2010) prepared Clarithromycin Hydrophilic 
floating matrix tablets by using different grades of polymer (HPMC) of varying 
concentrations, sodium bicarbonate and MCC by direct compression technique. Tablets 
of optimized formulation had good floating property as BLT in 50secs and remain 
buoyant for more than 12 h along with good swelling behaviors. Hydrophilic matrix 
floating tablets of Clarithromycin were developed to increase the gastric residence time 
which leads to increased bioavailability by giving sufficient time to release the drug in GI 
tract. 
D. M. Sakarkar56 et al., (2010) developed carbamazepine floating tablet 
containing Hydroxypropyl methylcellulose (HPMC) of different viscosity grades and 
ethyl cellulose. It was found that both HPMC viscosity, the presence of ethyl cellulose 
and their interaction had significant impact on the release and floating properties of the 
delivery system.  The observed difference in the drug release and the floating properties 
of GFDDS could be attributed to the difference in the basic properties of three polymers 
(HPMC K4M, K15M and ethyl cellulose) due to their water uptake potential and 
functional group substitution. 
Sharad N. Shinde57 et al., (2010) developed floating tablet of salbutamol 
sulphate by wet granulation method using hydroxypropyl methylcellulose as a release 
retardant material, sodium bicarbonate and Citric acid was incorporated as a gas-
generating agent.  Addition of Citric acid caused the enhancement in drug release and 
disintegration of tablet that was retarded by incorporation of stearic acid in the 
formulation.  The in-vitro drug release followed Korsemeyer-Peppas kinetics and the 
drug release mechanism was found to be of anomalous type. The similarity factor f2 was 
found to be 78.19 for the developed formulation indicating the release was almost similar 
to that of the marketed formulation. 
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Sameer Singh58 et al., (2011) studied the floating tablet of Captopril using 
different viscosity grades of hydroxypropyl methylecellulose K100M, K15M and K4M 
were used as a floating polymer. Lactose and citric acid were used in different 
concentration as a channeling and chelating agent had significant effect on the release of 
the drug from hydrophilic matrix tablet. The in-vitro release profiles of drug from all the 
plots shows high linearity (r2= 0.9813 to 0.9954).  Results revealed that the floating 
formulation of the Captopril is the best formulation to obtain better therapeutic effect and 
hydroxypropyl methylcellulose at a concentration of 35% up to some extent it increases 
the bioavailability of the drug to retain the dosage form on the desired site for effective 
period of the time. 
P. N. Kendre59 et al., (2010) prepared floating matrix theophylline tablet by 
direct compression method using gas generating agent (sodium bicarbonate) and various 
viscosity grades of hydrophilic polymers (HPMC K15M, K4M; HPC and Carbapol 
934P). The release rate could efficiently be modified by varying the matrix forming 
polymer, the use of  polymer blends and the addition of water soluble or water insoluble 
fillers (such as dicalcium phosphate, lactose or mannitol). Fitting the in-vitro drug release 
data to Korsmeyer equation indicated that diffusion along with erosion could be the 
mechanism of drug release. 
Vishnu M Patel60 et al., (2009)  developed gastro-retentive tablets for verapamil 
hydrochloride using different hydrocolloid polymers including Carbopol (CP 934P; CP 
940P), Hydroxypropyl methylcellulose (HPMC K4M; HPMC K15M; HPMC E15) and 
Xanthan gum by direct compression technology. All tablet formulations shown good in-
vitro buoyancy by adding an effervescent mixture of sodium bicarbonate and anhydrous 
citric acid.  The optimized formulation containing Xanthan gum released approximately 
97.89% drug in 24 h in-vitro dissolution study, while the buoyancy lag time was 24.6 ± 
3.2 sec and the tablet remained buoyant for > 24h. Zero order and non-Fickian release 
transport was confirmed as the drug release mechanism for the selected tablets.  
 Satish Singh Kadian61 et al., (2010) formulated floating celecoxib matrix tablet 
by directly compression technique using Hydroxypropyl Methyl Cellulose (HPMC), 
Ethyl Cellulose (EC) alone and in combination and effervescent sodium bicarbonate 
(NaHCO3). The final optimized formulation released approximately 92.5% drug in 24 h 
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in-vitro, while the floating lag time was not more than 0.35 min and the tablet remained 
floatable throughout all studies. Final formulation followed the physical appearance, drug 
content, floatability or in vitro dissolution pattern after storage at 45°C/75% RH for three 
months. 
R. S. Thakur62 et al., (2006) formulated floating Clarithromycin matrix tablets 
containing hydroxypropylmethylcellulose (HPMC), drug and different additives were 
compressed using wet granulation and D-optimal design technique. The optimized 
formulation was obtained using 62.5% clarithromycin, 4.95% HPMC K15M, 18.09% 
HPMC K4M, 12.96% sodium bicarbonate which gave floating lag time < 30 s with a 
total floating time > 10 h, in-vitro release profile very near to the target in-vitro release 
profile and follows anomalous diffusion as well as zero order pattern of release. 
Ziyaur Rahman63 et al., (2006) developed bilayer-floating captopril tablet by 
direct compression technology using HPMC, K-grade and effervescent mixture of citric 
acid and sodium bicarbonate formed the floating layer. The release layer contained 
captopril and various polymers such as HPMC-K15M, PVP-K30 and Carbopol 934p, 
alone or in combination with the drug. Final formulation released approximately 95% 
drug in 24 h in vitro, while the floating lag time was 10 min and the tablet remained 
floatable throughout all studies. Final formulation followed the Higuchi release model 
and showed no significant change in physical appearance, drug content and in-vitro 
dissolution pattern after storage at 45°C/75% RH for 3 months. 
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2.2. LITERATURE REVIEW ON ATORVASTATIN CALCIUM: 
Jayabalan nirmal64 et al., (2008) formulated and evaluated bilayer tablets 
consisting of atorvastatin calcium (AT) as an immediate release layer using super 
disintegrant croscarmellose sodium and nicotinic acid (NA) as an extended release layer 
using hydroxypropylmethyl cellulose (HPMC K100M). Both the matrix and bilayer 
tablets were evaluated for post compression parameters as drug content uniformity and 
subjected to in-vitro drug release studies. The amount of AT and NA released at different 
time intervals were estimated by HPLC method and drug release form polymer content 
by thermogravimetry/ differential thermal analysis (TG/DTA). The results indicated that 
the bilayer tablets could be a potential dosage form for delivering AT and NA. 
Subhadeep Chowdjury65 et al., (2010) studied glimepride and atorvastatin 
calcium in immediate release tablet formulation and evaluated, the effects of two 
independent variables were taken carboxymethylcellulose sodium (CMC-Na) (10mg, 
12.5mg and 15 mg) and sodium starch glycolate (SSG) (2.5 mg, 5mg and 7.5mg) on drug 
release from the tablet in order to optimize the formulation by 2 factor 3 level factorial 
design. It shows that SSG has more effect than CMC-Na on the tablet formulation and 
formulation with 14.78 mg of CMC-Na and 7.5 mg of SSG is the optimized formulation. 
The optimized formulation had showed dissolution profiles that were closed to predicted 
values. 
Patel Geeta M66 et al., (2010) prepared once a day regioselective dual component 
tablet of Atorvastatin Calcium (ATC) and Metoprolol Succinate (MP) by direct 
compression technique. The amount of polymer blends was optimized using 32 full 
factorial design.  All formulations floated for more than 18-20 h. More than 90% of ATC 
was released within 1 h. HPMC K100M and polyox WSR N-60K sustained the release of 
MP from the controlled release layer for more than 20 h. Diffusion exponents (n) were 
determined for all the formulations (0.45-0.89), so predominant drug release mechanism 
is non-Fickian (anomalous) transport. Therefore, biphasic drug release pattern was 
successfully achieved through the formulation of floating bilayer tablets. 
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Chapalamadugu Ugandhar67 et al., (2011) formulated immediate release drug 
combination as Atorvastatin (antihyperlipidemic) and Gliclazide (antidiabetic). Since 
Atorvastatin has t1/2 is near about 5 h so its release was retarded. HPMC was used as a 
retardant material. Two grades of Hydroxy Propyl MethylCellulose-4000cps and 100cps 
were used. The tablets were prepared by wet granulation method had undergone in-vitro 
dissoilution study.  For Atorvastatin only 2 h of dissolution study was performed and its 
release was found to be 97.6%. For Gliclazide dissolution study was performed up to 
complete 8 h and its release was found to be 89.314% and release rate was found to be 
nearly similar to marketed product. 
Kirti Rode68 et al., (2011) developed Atorvastatin calcium flim coated tablet by 
wet granulation technique. All the physical parameters of all batches were determined, 
from which optimized batch was found to comply with the standard due to its maximum 
amount of drug was released. The optimized formulation of film coated tablets was 
formulated by using PEG 6000 as a Plasticizer and HPMC as a Polymer, which showed 
dissolution profile similar to market product.  
N.Arunkumar69 et al., (2009) formulated Atorvastatin calcium (AT-Ca) 
nanosuspensions to improve the solubility and dissolution characteristics of a poorly 
soluble drug (AT-Ca) using nanosuspension technology. The drug AT-Ca nanoparticles 
were successfully prepared by high pressure homogenization and were evaluated for its 
various solid state characteristics. Crystallinity of the drug was also evaluated by 
performing thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC) 
and powder X-ray diffraction (PXRD) to denote eventual transformation to amorphous 
state during the homogenization process. Finally, crystalline AT-Ca was converted to 
amorphous form and exhibit improved dissolution and higher solubility leads to a 
significant impact in the oral bioavailability of the drug.  
Sachin V. Wankhede70 et al., (2010) developed Atorvastatin calcium amorphous 
into immediate release tablets. Atorvastatin calcium (amorphous) is highly susceptible to 
hydrolysis and oxidation, so wet granulation method was avoided. All the batches were 
done by dry granulation method by roller compaction and it under goes pre-compression 
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and post-compression parameters.  In-vitro dissolutions were performed and the 
dissolution profile of optimized formulation was matched perfectly with marketed 
(innovator) formulation and f2 value was found to be excellent. It can be concluded that 
the immediate release tablet was beneficial for delivering the drug which needs faster 
release to achieve the immediate action. 
S.Mohideen71 et al., (2011) formulated bilayered tablets consisting of 
Atorvastatin calcium (AC) as an immediate release layer and Metformin Hydrochloride 
(MH) as a sustained release layer.  The in-vitro release profile showed the desired 
biphasic behavior. The MH released for more than 12 h, where as Atorvastatin calcium 
dissolved within 45 min. Bilayer tablet prepared from optimized formula was found to be 
best suited method for fixed dose combination of sustained release MH and immediate 
release AC. 
Asha S. John72 et al., (2010) formulated and evaluated buccoadhesive drug 
delivery system for Atorvastatin calcium  using the bioadhesive polymers Carbopol 934P 
(CP), Sodium CMC, Hydroxy ethyl cellulose (HEC) and Sodium alginate (Na-alginate) 
along with ethyl cellulose as an impermeable backing layer. All the formulations gave the 
satisfactory results in terms of bioadhesive performance, physical and mechanical 
properties and surface pH. The swelling index was proportional to CP content and 
inversely proportional to sodium CMC content. The formulation containing CP and Na-
CMC in the ratio of 3:2 (F2) was optimized based on good bioadhesive strength (19.0 ± 
0.30 g) and sustained in-vitro drug permeation (85.68 % for 6 h). The chosen tablet 
containing 8 mg of Atorvastatin calcium performed 6 h sustained drug release with 
desired therapeutic concentration. 
N Arunkumar73 et al., (2008) prepared formulations of atorvastatin calcium 
floating tablets containing varying proportions of polymers like HPMC K4M and Ethyl 
cellulose and fixed amount of gas generating agent as Sodium bicarbonate and 
hydrophobic meltable material like bees wax by melt granulation technique. The prepared 
tablets remained buoyant for more than 8 h in the release medium. The data obtained 
from in-vitro dissolution studies of all the four formulations were F1, F2, F3 and F4 
released 36.88%, 34.77%, 42.17% and 48.51% respectively at the end of 8 h.  
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3. AIM OF THE WORK 
Oral drug delivery system is the most popular delivery system due to its ease of 
administration. In the past, oral route has been explored for the systemic delivery of drugs 
through different types of dosage forms. However the drug or the active moiety must be 
absorbed well throughout the Gastrointestinal Tract (GIT) in order to produce an 
optimized therapeutic effect. Absorption may be hindered, if there is a narrow absorption 
window for drug absorption in the GIT or if the drug is unstable in the GI fluids. Thus the 
real challenge is to develop an oral controlled release dosage form not only to prolong the 
delivery but also to prolong the retention of the dosage form in the stomach or small 
intestine until the entire drug is released. 
One of the most important approaches to control the retention of drug delivery 
system in GIT is by adopting Gastro Retentive Drug Delivery Systems (GRDDS). Such 
retention systems are important for drugs that are degraded in the intestine or drugs 
undergo rapid clearance in intestine like Atorvastatin calcium. 
¾ Atorvastatin calcium, an anti-hyperlipidemic drug used in the treatment of 
dyslipidemia and the prevention of cardiovascular disease was used as a model drug to 
develop a controlled release formulation. 
¾ Atorvastatin calcium has more absorption in acidic medium and Tmax is very 
rapid as within 1-2 h. Once the drug reaches the intestine it was rapidly undergo 
elimination. Hence the present study was aimed to develop a controlled release 
formulation of Atorvastatin calcium. 
¾ Atorvastatin calcium is taken by the people as a long term therapy; the major side 
effect experienced by the patients was myopathy, rhabdomyolysis due to more 
concentration of drug in the blood. Hence the present study is to release the drug in a 
required quantity to the body for that we planned to develop a controlled release 
formulation of Atorvastatin calcium. 
¾ The best formulation is to be selected on the basis of evaluation characteristics. 
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4. PLAN OF WORK 
1. Preparation of standard calibration curve for Atorvastatin Calcium. 
2. Optimizing the quantity of gas generating agent for the total tablet weight 
3. Selection of polymers and polymer concentrations. 
4. Compatibility study between drug and selected polymers. 
•   By Fourier Transform Infrared Spectroscopy 
5. Formulation of granules. 
6. Pre-compressional evaluation studies. 
• Angle of Repose 
• Bulk Density 
• Tapped Density 
• % Compressibility 
• Hausner’s Ratio 
7. Formulation of tablets. 
8. Post-compressional evaluation studies. 
• Weight variation 
• Thickness 
• Hardness 
• Friability 
• Drug content 
• Buoyancy lag time 
• Buoyancy time 
9. Selection of best formulation. 
10. In-vitro dissolution studies. 
11. Stability studies. 
12. Data analysis.(drug release kinetics) 
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5.1 MATERIALS AND METHODS 
 
S.No. MATERIALS NAME OF THE 
MANUFACTURER 
1 Atorvastatin calcium MOREPEN Laboratories Ltd., 
Solan (Himachal Pradesh) 
2 HPMC-Methocel 
(HPMC K4M,K15M,K100M) 
Colorcon Asia Pvt., Ltd., 
Goa. 
3 Croscarmellose sodium Ozone International, Mumbai. 
4 Crospovidone C.Chem, pharma Ltd., Bangalore. 
5 Avicel PH-102 Medreich, Bangalore. 
6 Polyethylene Oxide WSR 303  Medreich, Bangalore. 
7 Sodium bicarbonate    Ranbaxy Laboratories Ltd., 
Guragan, India. 
8 Talc      Loba Chemie Pvt Ltd., Mumbai.  
9 Magnesium stearate    Loba Chemie Pvt Ltd., Mumbai. 
10 Lactose DC     Juggat Pharmaceuticals Ltd., 
Bangalore. 
 
         
  
MATERIALS AND METHODS 
 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai   35 
 
5.1.1 INSTRUMENTS AND EQUIPMENTS  
S.No. INSTRUMENTS NAME OF THE MANUFACTURER 
1. Digital balance  Santorious BT 323S, Germany. 
2. Moisture analyzer  Santorious YCS 01-522-00, Germany. 
3. Hot air oven    C.S. Medical Pvt Ltd. 175-10, Chennai. 
4. 16 station Tablet compression 
Machine 
Elit Jemkay Engineers Pvt Ltd., Ahmedabad. 
5. Monsanto Hardness Tester      Scientific Engineering Corp, Delhi. 
6. Friability Testing Apparatus  Roche Friabilitor, EF-2, Bombay. 
7. Dissolution Test Apparatus  Electrolab TDT-08l, Bombay. 
8. U.V.Spectrophotometer  Shimadzu-uv-1601, Japan. 
9. FTIR  Shimadzu 8300, Japan. 
10. Digital pH meter Eutech cyber scan 500, Singapore. 
11. Sonnicator Santorious Flexit Lab, Geramany. 
12. Sieves  Campbell Electronics, Bombay. 
13. Bulk Density Apparatus  Campbell Electronics, Bombay. 
14. Digital Vernier Calipers   Mitutoyo Measuring Instruments (Suzhou) 
Co., Ltd. China. 
15. Thermogravimetry/Differential 
Thermal Analyzer 
SDT Q 600, India. 
16. Stability Chamber    Osworld, Mumbai. 
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5.1.2. DRUG PROFILE74,75 
MOLECULAR STRUCTURE OF ATORVASTATIN: 
                      
IUPAC NAME: 
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-
3,5-dihydroxyheptanoate 
ATORVASTATIN IDENTIFIERS: 
CAS number: 134523-00-5 
Category: Anti-Hyperlipidemic 
Bio Pharmaceutical Classification System: Class-II 
CHEMICAL DATA: 
Formula: C33H35FN2O5    
Mol. Mass: 558.64 g/mol 
Solubility: soluble in methanol 
DESCRIPTION: 
 Atorvastatin was first synthesized in 1985 by Bruce Roth while working at 
Parke-Davis Warner-Lambert Company (now Pfizer).Atorvastatin is a member of the 
drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque 
and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, 
atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue 
that plays a key role in production of cholesterol in the body. 
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With 2008 sales of US$12.4 billion, Lipitor was the top-selling branded 
pharmaceutical in the world. U.S. patent protection was scheduled to expire in June 2011. 
However, Pfizer made an agreement with Ranbaxy Laboratories that delayed the generic 
launch in the U.S. until November 30, 2011. 
 The primary use of atorvastatin is for the treatment of dyslipidemia and the 
prevention of cardiovascular disease. It is recommended to be used only after other 
measures such as diet, exercise, and weight reduction have not improved cholesterol 
levels.  
PHARMACOKINETIC DATA74: 
Absorption 
Atorvastatin is rapidly absorbed after oral administration; maximum plasma 
concentrations occur within 1 to 2 h. Extent of absorption increases in proportion to 
atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is 
approximately 14% and the systemic availability of HMG-CoA reductase inhibitory 
activity is approximately 30%. The low systemic availability is attributed to presystemic 
clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food 
decreases the rate and extent of drug absorption by approximately 25% and 9%, 
respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether 
atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower 
(approximately 30% for Cmax and AUC) following evening drug administration 
compared with morning. However, LDL-C reduction is the same regardless of the time of 
day of drug administration.  
Distribution 
Mean volume of distribution of atorvastatin is approximately 381 liters. 
Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 
0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, 
atorvastatin is likely to be secreted in human milk.  
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Metabolism 
Atorvastatin is extensively metabolized to ortho- and parahydroxylated 
derivatives and various beta-oxidation products. In-vitro inhibition of HMG-CoA 
reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. 
Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is 
attributed to active metabolites. In-vitro studies suggest the importance of atorvastatin 
metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of 
atorvastatin in humans following coadministration with erythromycin, a known inhibitor 
of this isozyme. In animals, the ortho-hydroxy metabolite undergoes further 
glucuronidation. 
Excretion 
Atorvastatin and its metabolites are eliminated primarily in bile following hepatic 
and/or extra-hepatic metabolism; however, the drug does not appear to undergo 
enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans 
is approximately 14 h, but the half-life of inhibitory activity for HMG-CoA reductase is 
20 to 30 h due to the contribution of active metabolites. Less than 2% of a dose of 
atorvastatin is recovered in urine following oral administration. 
MECHANISM OF ACTION: 
 As with other statins, atorvastatin is a competitive inhibitor of HMG-CoA 
reductase. Unlike most others, however, it is a completely synthetic compound. HMG-
CoA reductase catalyzes the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) to mevalonate, which is the rate-limiting step in hepatic cholesterol 
biosynthesis. Inhibition of the enzyme decreases de-novo cholesterol synthesis, 
increasing expression of low-density lipoprotein receptors (LDL receptors) on 
hepatocytes. This increases LDL uptake by the hepatocytes, decreasing the amount of 
LDL-cholesterol in the blood. Like other statins, atorvastatin also reduces blood levels of 
triglycerides and slightly increases levels of HDL-cholesterol. 
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 In clinical trials, drugs that block cholesterol uptake like ezetimibe combine with 
and complement those that block biosynthesis like atorvastatin or simvastatin in lowering 
cholesterol or targeting levels of LDL.  
SIDE EFFECTS: 
 Minor effects like: Headache; nausea. Severe allergic reactions in over dosage 
condition like (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of 
the mouth, face, lips, or tongue); calf pain; chest pain; confusion; dark urine; fast, slow, 
or irregular heartbeat; fever, chills, or persistent sore throat; increased coughing or 
coughing up blood; muscle pain, tenderness, or weakness (with or without fever and 
fatigue); pale stools; red, swollen, blistered, or peeling skin; severe or persistent dizziness 
or light headedness; severe or persistent nausea, stomach pain, or vomiting; severe pain 
or swelling in the ankles, feet, or legs; shortness of breath; unusual bruising or bleeding; 
yellowing of the skin or eyes. 
CONTRAINDICATION:   
• Acute liver disease: cholestasis, hepatic encephalopathy, hepatitis, and jaundice 
• Unexplained elevations in AST or ALT levels 
• Pregnancy 
• Breastfeeding 
 Precaution must be taken when treating with atorvastatin, because rarely it may 
lead to rhabdomyolysis, it may be very serious leading to acute renal failure due to 
myoglobinuria. If rhabdomyolysis is suspected or diagnosed, atorvastatin therapy should 
be discontinued immediately. The likelihood of developing a myopathy is increased by 
the co-administration of cyclosporine, fibric acid derivatives, erythromycin, niacin, and 
azole antifungals.  
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PREGNANCY AND LACTATION: 
Atorvastatin is absolutely contraindicated in pregnancy, it is likely to cause harm 
to fetal development because of the importance of cholesterol and various products in the 
cholesterol biosynthesis pathway for fetal development, including steroid synthesis and 
cell membrane production. It is not recommended for nursing mothers to take atorvastatin 
due to the possibility of adverse reactions in nursing infants, since experiments with rats 
indicate that atorvastatin is likely to be secreted into human breast milk.  
FORMULATIONS: 
 All atorvastatin formulations are available as solid dosage form.  It is under the 
brand name of Lipitor by Pfizer labs, a-vin by besthochem , atorva by zydus cadila, 
Atocor by Dr.Reddy’s labs, Ateven vy apotex, atorbest by cadila labs, Atorec by Emcure, 
Atorfit by Ajanta, atoril bu auroindo, Atorlip by Cipla pharmaceuticals.  
COMBINATION WITH OTHER DRUGS: 
 Co-administration of Atorvastatin with one of CYP3A4 inhibitors like 
itraconazole, telithromycin and voriconazole, may increase serum concentrations of 
atorvastatin, which may lead to adverse reactions. bosentan, fosphenytoin, and phenytoin, 
which are CYP3A4 inducers, can decrease the plasma concentrations of atorvastatin. 
Antacids can rarely decrease the plasma concentrations of atorvastatin but do not affect 
the LDL-C-lowering efficacy. Niacin is also proved to increase the risk of myopathy or 
rhabdomyolysis. Statins may also alter the concentrations of other drugs, such as warfarin 
or digoxin, leading to alterations in effect or a requirement for clinical monitoring.  
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5.1.3 EXCIPIENTS76 
1. HYDROXY PROPYL METHYL CELLULOSE88 
Nonproprietary Names: 
          USP, BP  :  Hypromellose                    
          JP           :  Hydroxypropylmethylcellulose  
          Ph Eur    :  Hypromellosum 
Functional Category: 
          USP      : Suspending agent and / or viscosity increasing agent, tablet binder,  
   coating agent. 
          B.P.     : Viscosity increasing agent, adhesive anhydrous ointment ingredient 
          Others : Film former, emulsion stabilizer. 
Synonyms: Methyl Hydroxy Propyl Cellulose (MHPC), Methyl cellulose Propylene 
glycol ether, Methocel, Metolose, Tylopur, Propylene glycol ether of methylcellulose. 
Chemical Name:  Cellulose, 2-Hydroxypropylmethyl ether.  
 
                       n: degree of polymerizetion;  R:-H,-CH3 or CH2CH(OH)CH3 
Empirical Formula :  C8H15O6- (C10H18O6 )n – C8H15O5 
Molecular Weight:      86,000 (Approximately) 
Description: Odorless, tasteless, white or off-white fibrous or granular powder.  
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Typical Properties: 
           Browning temperature   :  190-200◦C 
           Bulk Density                  :  0.25-0.70g/cm2 
           Specific Gravity             :  1.26-1.31 
           Surface tension              :  42-56dynes/cm (2% aqueous solution) 
Solubility: HPMC is soluble in water and some organic solvents. Its aqueous solution is 
of high transparency and stable property. The solubility varies with the viscosity. The 
lower the viscosity, the higher is the solubility. The different grades of HPMCs vary in 
some properties and its solubility in water is not affected by pH. It is practically insoluble 
in ethanol, ether and chloroform.  
Moisture Content: HPMC absorbs moisture from the atmosphere. The amount of water 
absorbed depends upon the initial moisture content and the temperature and the relative 
humidity of the surrounding air.  
Stability: Very stable in dry conditions. Solutions are stable at pH 3 to 11.0. 
Storage Condition: It should be stored in well closed containers in a cool and dry place. 
Incompatibilities:  Oxidizing agents. 
Safety: It is a non-toxic and non-irritant polymer. 
Regulatory Status: HPMC is accepted for use as a food additive in Europe, included in 
the FDA Inactive Ingredients Guide, non-parenteral medicines licensed in the UK and in 
the Canadian List of Acceptable Non-medicinal Ingredients. 
Role of HPMC in Controlled Release Systems: In a hydrophilic matrix system, HPMC 
is uniformly incorporated throughout the tablet. Upon contact with water, it hydrates the 
outer tablet surface to form a gel layer. The rate of diffusion of drug out of the gel layer 
and the rate of tablet erosion control the overall dissolution rate and drug delivery. 
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2.  SODIUM BICARBONATE 
Nonproprietary Names: 
BP: Sodium bicarbonate 
JP: Sodium bicarbonate 
PhEur: Natrii hydrogenocarbonas 
USP: Sodium bicarbonate 
Synonyms: 
Baking soda; E500; Effer-Soda; monosodium carbonate; Sal de Vichy;  
sodium acid carbonate; sodium hydrogen carbonate. 
Chemical Name: 
Carbonic acid monosodium salt 
Empirical Formula and Molecular Weight:  NaHCO3; 84.01 
Structural Formula:  NaHCO3 
Functional Category:  Alkalizing agent; therapeutic agent. 
Applications in Pharmaceutical Formulation or Technology: 
Sodium bicarbonate is generally used in pharmaceutical formulations as a source 
of carbon dioxide in effervescent tablets and granules. It is also widely used to produce or 
maintain an alkaline pH in a preparation. 
Tablets may also be prepared with sodium bicarbonate alone since the acid of 
gastric fluid is sufficient to cause effervescence and disintegration. Sodium bicarbonate is 
also used in tablet formulations to buffer drug molecules that are weak acids, thereby 
increasing the rate of tablet dissolution and reducing gastric irritation. 
Sodium bicarbonate has been used as a gas forming agent in alginate raft systems 
and in floating, controlled-release oral dosage forms of furosemide, cisapride and 
atorvastatin. Tablet formulations containing sodium bicarbonate have been shown to 
increase the absorption of paracetamol, and improve the stability of levothyroxine. 
Therapeutically, sodium bicarbonate may be used as an antacid, and as a source of 
the bicarbonate anion in the treatment of metabolic acidosis. Sodium bicarbonate may 
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also be used as a component of oral rehydration salts and as a source of bicarbonate in 
dialysis fluids. 
Table:1 Uses of Sodium bi carbonate 
Use Concentration (%) 
Buffer in tablet 10-40 
Effervescent tablet 25-50 
Isotonic injection/infusion 1.39 
Description and Solubility: 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with a saline, 
slightly alkaline taste. The crystal structure is monoclinic prisms. Grades with different 
particlesizes, from a fine powder to free-flowing uniform granules, are commercially 
available. Sodium bicarbonate slightly soluble in water but practically insoluble in ether 
and ethanol (95%).  
Typical Properties 
Acidity/alkalinity: pH = 8.3 for a freshly prepared 0.1M aqueous solution at 258◦C; 
alkalinity increases on standing, agitation, or heating. 
Density (bulk): 0.869 g/cm3 
Density (tapped): 1.369 g/cm3 
Density(true): 2.173 g/cm3 
Freezing point depression: 0.3818◦C (1% w/v solution) 
Melting point: 2708◦C (with decomposition) 
Moisture content: Below 80% relative humidity, the moisture content is less than 1% 
w/w. Above 85% relative humidity, sodium bicarbonate rapidly absorbs excessive 
amounts of water and may start to decompose with loss of carbon dioxide. 
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Stability and Storage Conditions: 
When heated to about 508◦C, sodium bicarbonate begins to dissociate into carbon 
dioxide, sodium carbonate, and water; on heating to 250–308◦C, for a short time, sodium 
bicarbonateis completely converted into anhydrous sodium carbonate. 
Sodium bicarbonate powder is stable below 76% relative humidity at 258◦C and 
below 48% relative humidity at 408◦C. At 54% relative humidity, the degree of pyrolytic 
decarboxylation of sodium bicarbonate should not exceed 4.5% in order to avoid 
detrimental effects on stability.  
Sodium bicarbonate is stable in dry air but slowly decomposes in moist air and 
should therefore be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Sodium bicarbonate reacts with acids, acidic salts, and many alkaloidal salts, with 
the evolution of carbon dioxide. Sodium bicarbonate can also intensify the darkening of 
salicylates. 
In powder mixtures, atmospheric moisture or water of crystallization from another 
ingredient is sufficient for sodium bicarbonate to react with compounds such as boric 
acid oralum.  
In liquid mixtures containing bismuth subnitrate, sodium bicarbonate reacts with 
the acid formed by hydrolysis of the bismuth salt. 
In solution, sodium bicarbonate has been reported to be incompatible with many 
drug substances such as ciprofloxacin, amiodarone, nicardipine, and levofloxacin. 
Method of Manufacture: 
Sodium bicarbonate is manufactured either by passing carbon dioxide into a cold 
saturated solution of sodium carbonate, or by the ammonia–soda (Solvay) process, in 
which first ammonia and then carbon dioxide is passed into a sodium chloride solution to 
precipitate sodium bicarbonate while the more soluble ammonium chloride remains in 
solution. 
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Safety: 
Sodium bicarbonate is used in a number of pharmaceutical formulations including 
injections and ophthalmic, otic, topical,and oral preparations. 
Sodium bicarbonate is metabolized to the sodium cation, which is eliminated from 
the body by renal excretion, and the bicarbonate anion, which becomes part of the body’s 
bicarbonate store. Any carbon dioxide formed is eliminated via the lungs. When used as 
an excipient, sodium bicarbonate is generally regarded as an essentially nontoxic and 
nonirritant material. 
Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection and gloves are recommended. 
Related Substances:  Potassium bicarbonate. 
Description: Odorless, white, crystalline powder with a saline, slightly alkaline taste.  
 
3. MICRO CRYSTALLINE CELLULOSE: 
Non proprietary names 
BP: Micro crystalline cellulose 
JP: Micro crystalline cellulose 
PhEur: Cellulosum microcrystalanium 
 USPNF: Micro crystalline cellulose 
Synonyms: 
 Avicel PH, Celex, Cellulose gel, Celphere, Ceolus KG, crystalline Cellulose, 
E460, Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur. 
Chemical name: Cellulose 
Empirical Formula: (C6H10O5) n Where n=220   Molecular weight 36000 
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Functional category:    Adsorbent, suspending agent, tablet and capsule diluent, tablet 
disintegrants 
Application in Pharmaceutical formulation or technology: 
 Micro crystalline cellulose pH 101 is widely used in pharmaceuticals, primarily as 
a binder/diluent in oral tablet and capsule formulations where it is used in both wet 
granulation and direct compression processes. In addition to its use as a binder/diluent, 
micro crystalline cellulose pH 101 also has some lubricant and disintegrant properties 
that make it useful in tableting. 
 
Table:2 Uses of Microcrystalline cellulose 
Use Concentration (% w/w) 
Adsorbent 20-90 
Anti-adherent 5-20 
Capsule binder/diluents 20-90 
Tablet disintegrant 5-15 
Description: 
Micro crystalline cellulose pH 101 is purified, partially depolymerised cellulose that 
occurs as a white, odourless, tasteless, crystalline powder composed of porous particles. 
It is commercially available in different particle sizes and moisture grades that have 
different properties and applications. 
 Solubility:Slightly soluble in 5 % w/v sodium hydroxide solution, practically insoluble 
in water, dilute acids, and most organic solvents. 
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4. PURIFIED TALC:  
Synonyms: 
 Hydrous magnesium calcium silicate. 
Chemical Name:Talc. 
Empirical Formula: 
 Approximate Mg6(Si2O5)4(OH)4 
Functional Category: 
 Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant. 
 
Application in Pharmaceutical Formulation: 
Table:3 Uses of Purified Talc 
Use Concentration (%) 
Dusting powder 90.0–99.0 
Glidant and tablet lubricant 1.0–10.0 
Tablet and capsule diluents 5.0–30.0 
Talc was widely used in oral solid dosage formulations as a lubricant, diluent and 
dissolution retardant in development of controlled-release products. Talc is also used as a 
lubricant in tablet formulations; in a novel powder coating for extended-release pellets; 
and as an adsorbent. In topical preparations, talc is used as a dusting powder, although it 
should not be used to dust surgical gloves. Talc is a natural material; it may therefore 
frequently contain microorganisms and should be sterilized when used as a dusting 
powder. Talc is additionally used to clarify liquids and is also used in cosmetics and food 
products, mainly for its lubricant properties. 
Description: 
Talc is very fine, white to grayish white, odorless, impalpable, crystalline powder. 
It adheres readily to skin and soft to touch and free from grittiness. 
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pH: 7-9. 
Solubility:Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Stability and Storage: 
 Talc is a stable material and may be sterilized by heating at 160°C for not less 
than 1 h. It may also be sterilized by exposure to ethylene oxide or gamma irradiation. 
Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibility: It is incompatible with quaternary ammonium compounds. 
 
5. MAGNESIUM STEARATE:  
Synonyms:  
Magnesium octadecanoate, Octadecanoic acid, Stearic acid. 
Empirical Formula: C36H7OMgO4;  
Molecular Weight: 591.34. 
Application in Pharmaceutical Formulation: 
 Primarily used as lubricant in capsule and tablet at a concentration between 0.25% 
- 5.0% w/w. 
Description: 
Magnesium stearate is very fine, light white, precipitated or milled impalpable 
powder of low bulk density having a faint order of stearic acid and characteristic taste. 
The powder is greasy to touch and readily adheres to skin. 
Magnesium stearate is hydrophobic and may retard the dissolution of a drug from 
a solid dosage form; the lowest possible concentration is therefore used in such 
formulations. Capsule dissolution is also sensitive to both the amount of magnesium 
stearate in the formulation and the mixing time; higher levels of magnesium stearate and 
long mixing times can result in the formation of hydrophobic powder beds that do not 
disperse after the capsule shell dissolves. 
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An increase in the coefficient of variation of mixing and a decrease in the 
dissolution rate have been observed following blending of magnesium stearate with a 
tablet granulation. Tablet dissolution rate and crushing strength decreased as the time of 
blending increased; and magnesium stearate may also increase tablet friability. Blending 
times with magnesium stearate should therefore be carefully controlled. 
Loss on Drying:≤6.0%. 
Solubility: Practically insoluble in ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%). 
Incompatibility:  
    Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in product containing aspirin, 
some vitamins and most alkaloidal salts. 
 
6. LACTOSE ANHYDROUS 
Nonproprietary Names: 
BP: Anhydrous lactose 
JP: Anhydrous lactose 
PhEur: Lactosum anhydricum 
 USPNF: Anhydrous lactose 
Synonyms: 
  Anhydrous Lactose NF 60M; Anhydrous Lactose NF Direct Tableting; 
Lactopress Anhydrous; lactosum; lattioso; milk sugar; Pharmatose DCL 21; Pharmatose 
DCL 22; saccharum lactis; Super-Tab Anhydrous 
Chemical name: 
O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranose 
Empirical formula and Molecular weight: 
C12H22O11; 342.30. 
EXCIPIENTS LITERATURE 
 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai     51 
 
Functional category: 
Binding agent; directly compressible tableting excipient; lyophilization aid; tablet 
and capsule filler 
Description: 
Lactose occurs as white to off-white crystalline particles or powder. Several 
different brands of anhydrous lactose are commercially available which contain 
anhydrous β-lactose and anhydrous α-lactose. Anhydrous lactose typically contains 70–
80% anhydrous β-lactose and 20–30% anhydrous α-lactose. 
Applications in Pharmaceutical Formulation or Technology:  
Anhydrous lactose is widely used in direct compression tableting applications and 
as a tablet and capsule filler and binder. Anhydrous lactose can be used with moisture-
sensitive drugs due to its low moisture content. 
Melting Point:  
• 223.0°C for anhydrous α-lactose; 
• 252.2°C for anhydrous β-lactose; 
• 232.0°C (typical) for commercial anhydrous lactose 
Water Content:  
Loss on drying ≤0.5% and ≤1.0% water content for Anhydrous Lactose NF Direct 
Tableting and Anhydrous Lactose NF 60M; 0.2% loss on drying and 0.5% water content 
for Pharmatose DCL 21 (typical); 0.2% loss on drying. 
Solubility: Soluble in water; sparingly soluble in ethanol (95%) and ether 
Stability and storage condition: 
Mould growth may occur under humid conditions (80% RH and above). Lactose 
may develop a brown coloration on storage, the reaction being accelerated by warm, 
damp conditions; At 80°C and 80% RH, tablets containing anhydrous lactose have been 
shown to expand 1.2 times after one day. Lactose anhydrous should be stored in a well-
closed container in a cool, dry place. 
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Incompatibilities:  
Lactose anhydrous is incompatible with strong oxidizers. When mixtures 
containing a hydrophobic leukotriene antagonist and anhydrous lactose or lactose 
monohydrate were stored for six weeks at 40°C and 75% RH, the mixture containing 
anhydrous lactose showed greater moisture uptake and drug degradation. 
Method of Manufacture:  
 There are two anhydrous forms of lactose: α-lactose and β-lactose. The anhydrous 
forms that are commercially available may exhibit hygroscopicity at high relative 
humidities. Anhydrous lactose is produced by roller, drying a solution of lactose above 
93.5°C. The resulting product is then milled and sieved. Two anhydrous α-lactoses can be 
prepared using special drying techniques: one is unstable and hygroscopic, the other 
exhibits good compaction properties. However, these materials are not commercially 
available. 
Safety: 
Lactose is widely used in pharmaceutical formulations as a diluent and filler-
binder in oral capsule and tablet formulations. It may also be used in intravenous 
injections. Adverse reactions to lactose are largely due to lactose intolerance, which 
occurs in individuals with a deficiency of the intestinal enzyme lactase, and is associated 
with oral ingestion of amounts well over those in solid dosage forms. 
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5.2 METHODS:  
5.2.1 CONSTRUCTION OF STANDARD CURVE OF ATORVASTATIN 
CALCIUM79: 
 
By UV spectroscopy method: 
Atorvastatin calcium estimated spectrophotometrically at 246nm and it obeys beer -
lamberts law in the range of 2 – 20 mcg/ml.  
  
PREPARATION OF BUFFER:  
0.1N Hydrochloric Acid: 
Concentrated hydrochloric acid of 8.5 ml was taken in a 1000 ml standard flask 
containing distilled water and volume made up to 1000 ml with distilled water. 
 
PROCEDURE: 
1) Standard curve of Atorvastatin in 0.1N HCL: 
 
a) preparation of primary stock solution: 
Accurately weighed 100 mg of atorvastatin was taken in 100 ml standard flask. Then 
25ml of methanol added slowly to dissolve the drug completely. Then it was made up to 
volume 100 ml with 0.1 N HCL to a concentration of 1000 mcg / ml. 
b) preparation of secondary stock solution: 
From primary solution flask 2 ml was taken in 100 ml standard flask and made up to 
100 ml with 0.1N HCL to a concentration of 20 mcg / ml. 
c) sample solution : 
From the secondary stock solution aliquots ranging from 1 to 10 ml were pipetted out 
and diluted to 10 ml with 0.1N HCL to get the concentration of 2 to 20 mcg / ml then 
absorbance was measured at 246nm. 
A standard graph was plotted by keeping the known concentration on X axis and 
obtained absorbance on Y axis. 
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Table:4 Data for standard curve of Atorvastatin calcium in 0.1N HCL: 
 
Concentration ( mcg / ml ) Absorbance 
2 0.078 
4 0.142 
6 0.208 
8 0.269 
10 0.347 
12 0.414 
14 0.501 
16 0.557 
18 0.620 
20 0.682 
 
Figure:1 Standard curve of Atorvastatin calcium 
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6. EXPERIMENTAL INVESTIGATIONS 
 6.1 PREFORMULATION STUDIES:  
• Preformulation testing is an investigation of physical and chemical properties 
of drug substances alone and when combined with excipients. It is the first 
step in the rational development of dosage forms.  
• The overall objective of preformulation testing is to generate information 
useful to the formulation in developing stable and bioavailable dosage forms.  
• The use of preformulation parameters maximizes the changes in formulating 
an acceptable, safe, efficacious and stable product.  
• The drug (Atorvastatin Calcium) in powder form and granules were subjected 
to the following physical test for 3 times and average values were noted. 
6.2 Characterization of Drug 
6.2.1 UV- Spectrum Analysis of Drug77 
 Atorvastatin drug solution in pH 1.2 was scanned using UV-
Spectrophotometer between the range 200-400nm using pH 1.2 as blank.  
 
 6.2.2 I.R SPECTRUM FOR ATORVASTATIN CALCIUM:  
       Instrument used was Shimadzu FTIR-8300 spectrophotometer. In this study, 
potassium bromide disc method was employed. Both pure drug and its mixture with 
various grades of HPMC were subjected to IR studies (Table: 12-17). The powdered 
samples were intimately mixed with dry powdered potassium bromide and were 
compressed under 15 tones pressure in a hydraulic press to form a transparent disc. 
The disc was placed in IR spectrophotometer using sample holder and scanned from 
4000 to 400cm-1 in IR spectrometer. The IR spectrum of substances compared with 
that obtained concomitantly for the corresponding IP reference standard provides 
perhaps the most conclusive evidence of the identity of the substance.  
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6.2.3 DRUG – EXCIPIENTS COMPATIBILITY STUDIES:  
About 100 mg of Atorvastatin calcium alone and mixtures, consisting of 
Atorvastatin calcium with various excipients in 1:1 and 1: 10 ratios were taken in 
glass vials and kept at various accelerated condition [25oC / 60% RH, 30oC / 65% RH, 
40oC / 75% RH] in stability chamber. It is carried out for one month in open and 
closed glass vials. At the interval days of 1, 2, 3, 4, 5, 6,14, 21 and 30 days samples 
were withdrawn and physical characteristics like color change, if any were recorded. 
Finally the mixtures with no color change were selected for formulations.  
6.3 Evaluation  
Tablets were subjected to 2 types of evaluation, which are as follows 
• Pre-compressional evaluation  
• Post-compressional evaluation  
6.3.1. Pre-compressional Evaluation86 
Angle of Repose 
It is defined as the maximum angle possible between the surface of the pile of the 
powder and horizontal plane. Fixed funnel method was used. A funnel was fixed with 
its tip at a given height (h) above a flat horizontal surface to which a graph paper was 
placed. The granules were carefully poured through a funnel till the apex of the 
conical pile just touches the tip of the funnel. It was then calculated using the formula 
    Tan θ = h/r 
                            Where,  θ = Angle of Repose 
 h = Height of Pile 
 r  = Radius of the base of the pile 
Table:5  Angle of Repose 
S. No. Angle of Repose ( 0 ) Flow 
1. < 25 Excellent 
2. 25 – 30 Good 
3. 30 – 40 Fair 
4. > 40 Poor 
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Bulk Density  
 It is a ratio of mass of powder to bulk volume. The bulk density depends on 
particle size distribution, shape and cohesiveness of particles. Accurately weighed 
quantities of granules were carefully poured into graduated measuring cylinder 
through large funnel and volume was measured which is called initial bulk volume. It 
was expressed in gm/ ml and given by  
Bg
WgBD =  
Where,             BD = Bulk Density  
Wg = Weight of granules 
Bg = Bulk volume of granules 
Tapped Density:  
It is the ratio of total mass of the powder to the tapped volume of powder. The 
weight of sample equivalent to 10 g was filled in 100 ml graduated cylinder. The 
mechanical tapping of the cylinder was carried out at a rate of 300 drops per minute 
for 500 times from 3” height and the tapped volume Vf was noted. The tapped density 
was calculated in gm/ cm3 by the formula, 
(ρt) = M/Vf 
Where    ρt  - Tapped Density 
                            M = weight of sample powder taken 
                             Vf = tapped volume 
Carr’s Consolidation Index ( % Compressibility) 
 Carr’s Index explains flow properties of the granules. It is expressed in 
percentage and given by  
 
 100
Density Tapped
Density  Untapped-Density  TappedIndex ion Consolidat X=  
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Table:6  Consolidation Index 
S. No. Consolidation Index % Flow 
1. 5 – 12 Excellent 
2. 13 – 16 Good 
3. 17 – 21 Fair 
4. ≥ 40 Poor 
Hausner’s ratio: 
Tapped density and untapped density were measured and the Hausner’s ratio 
was calculated using the formula, 
                 Hausner’s ratio = ρt/ρo 
                                   Where, ρt = tapped density ;  
       ρo = untapped density 
    Table:7  Hausner’s Ratio 
S.NO Hausner’s Ratio Property 
1 
2 
0 - 1.2 
1.2 – 1.6 
Free flowing 
Cohesive powder 
  The results of physical properties of drug Atorvastatin calcium and powder 
blend are given in the Table No.18 and Table No.19 respectively. 
 
7.Formulation of floating tablet: 
FORMULATION DEVELOPMENT83,87 
Design of formula and composition: The design of tablets involved various 
compositions on the part of the formulator, to produce desired product properties. It 
involves the correct selection and balance of excipients, materials for active 
ingredients to achieve the desired response.  
Justification for the design of the composition: In addition to the active ingredient, 
Atorvastatin calcium 20mg SR tablets contained a number of inert materials as 
diluents, binder, glidant and lubricants, gas generating agent and polymers to impart 
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satisfactory processing, compression and release characteristics to the formulation. 
The justification for the inclusion of these functional additives is briefly described 
below: 
a. Diluents: They are inert materials added to increase the bulk in order to make the 
tablet with a desired particle size for compression. Calcium phosphate anhydrous, 
mannitol, sucrose and anhydrous lactose were used as diluents.  
b. Binders: Materials used to impart cohesive quality to the powdered materials are 
referred to as binders. They impart cohesiveness to the tablet formulation which 
ensures the tablet remaining intact after compression as well as improving the free 
flowing qualities by the formulation of granules of desired hardness and size. 
AVICEL PH102 was selected as binder in present study.  
c. Glidant: It is an inert material used to increase the flow property of the tablet 
blend. Here talc is used as a glidant. 
d.Lubricants: They prevent the adhesion of the tablet material to the surface of the 
dies and punches reducing inter-particle friction, facilitating the ejection of the tablet 
from the die cavity and improve the rate of flow of the tablet granulation. In the 
present study magnesium stearate was used as lubricant.  
e.Gas generating agent: It is the major ingredient, which play an important role in 
floating of the tablet in the gastric medium. Here sodium bicarbonate is used as a gas 
generating agent. 
f.polymer: It is used to control the release of drug from the tablet formulation. 
Different types of polymers are available as HPMC, PEO, HPC, etc,. 
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7.1. FORMULATION OF SUSTAINED RELEASE TABLET OF 
ATORVASTATIN CALCIUM:    
 
Composition of Atorvastatin Calcium 20mg Sustained Release Tablet 
I)  DIRECT COMPRESSION METHOD81: 
           To formulate Atorvastatin Calcium 20mg SR tablet by direct compression 
method.  
Table No: 8 FORMULA COMPOSITION 
S.No Ingredients (mg) Category Range 
1 Atorvastatin Calcium Active ingredient 20mg 
2 HPMC K15M Polymer 10%, 20% 
3 HPMC K100M Polymer 10%, 15%, 20% 
4 AVICEL PH102 Binder 5%, 10%, 15% 
5 Sodium Bicarbonate Gas generating 
agent 
15% 
6 Lactose Diluent q.s. 
7 Magnesium stearate Lubricant 0.5% 
8 Talc Glidant 1% 
Average weight of tablet   150mg 
Dissolution Profile Dissolution profile for 24th hour 
 
 
 
 
 
 
 
 
EXPERIMENTAL INVESTIGATIONS 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai                  61 
 
 
General Manufacturing procedure for all formulae in table no:8: 
Step 1: DISPENSING: All the materials are collected according to the above 
formula composition. 
 Step 2: SIFTING: 
a. Atorvastatin calcium, HPMC, avicel PH102, sodium bicarbonate, lactose were 
sifted and passed through # 40 mesh and collected in a double lined poly bag. 
b. Magnesium stearate, talc was passed through # 60 mesh and collected it in 
double lined poly bag separately.  
Step 3: MIXING: Then the major raw materials were mixed with the lubricant. 
Step 4: COMPRESSION: 
        Lubricated blend was compressed using 7mm flat round shaped punches plain on 
both sides in 16 station compression machine with average weight of 150mg. All the 
parameters of the compressed tablets are given in the Table:19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL INVESTIGATIONS 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai                  62 
 
 
6.3.2 Post-Compressional Evaluation90 
Weight Variation Test 
 Twenty tablets were weighed individually and average weight was calculated. 
The individual weights were then compared with average weight. The tablet passes 
the test if not more than two tablets fall outside the percentage limit and none of the 
tablet differs by more than double percentage limit.  
                                 100X
W
WW
PD
avg
indavg −=  
                                           where, 
     PD   =  Percentage Deviation  
Wavg =  Average weight of tablet 
Wind  =  Individual weight of tablet 
Table:10  Weight Variation 
S. No. Average Weight % Deviation 
1. 0.12g or less ± 10 
2. 
More than 0.12g but less than 
0.3g 
± 7.5 
3. 0.3g or more ± 5 
 
Thickness and Diameter: 
 The thickness and diameter of the tablets were carried out using vernier caliper 
(Mitutoyo corps, Japan). Five tablets were used for the above test from each batch and 
results were expressed in millimeter. 
Hardness 
 The Monsanto hardness tester was used to determine the tablet hardness. The 
tablet was held between affixed and moving jaw. Scale was adjusted to zero; load was 
gradually increased until the tablet fractured. The value of the load at that point gave a 
measure of the hardness of tablet. Hardness was expressed in Kg/ cm2.  
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Friability 
 Friability was determined using Roche Friabilator. Twenty tablets were 
weighed and placed in the friabilator and then operated at 25 rpm for four minutes. 
The tablets were then dedusted and weighed. It was expressed in percentage. 
Friability should be < 1%. 
The difference in the two weights is used to calculate the friability. 
         )1(100
0W
WXFriability −=  
                                         where,  
W0  =   Initial weight      
W   =   Final weight 
Drug Content 
 Drug content was determined to check dose uniformity in the formulations. 
The procedure adopted for determination of drug content as initially 10 tablets were 
weighed and powdered. A quantity equivalent to 100 mg of Atorvastatin calcium was 
taken in a 100 ml volumetric flask and dissolved in small volume of methanol and 
made up the volume with 0.1N HCL and filtered. An aliquot of 10 ml was pipetted 
out into 100 ml volumetric flask and made up the volume with distilled water. 
Absorbance was read at 246 nm using 0.1N HCL as a blank. 
Buoyancy Studies  
 The time taken by the tablet to emerge on to the surface is called the floating 
lag time or Buoyancy lag Time (BLT) and the total time for which the tablet floats on 
the media surface is the Buoyancy Time (BT). Buoyancy studies were carried out in 
glass beakers at pH 1.2. Lag time and floating time were noted. (Table: 36) 
In-vitro Release studies82 
 In-vitro release studies were carried out using pH 1.2 buffer as dissolution 
medium at 370 ± s0.50C and rotational speed of 75 rpm for 24 h. 5ml of dissolution 
medium was withdrawn at every 1h time intervals and then estimated 
spectrophotometrically.  Dissolution mechanism of the formulations was analyzed by 
plotting drug release versus time plot (Table: 20-31) 
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6.4 STABILITY STUDIES:78,89  
Stability is defined as the extent to which a product retains the contents within 
specified limit and throughout its period of storage and use i.e. shelf life, the same 
properties that it possesses at the time of manufacture. These studies were designed to 
increase the rate of chemical or physical degradation of the drug substance or product 
by using exaggerated storage conditions.  
Stability studies are important to prevent the economic repercussions of 
marketing of an unstable product, since subsequent withdrawal and reformulation 
may lead to considerable financial loss. From the point of view of safety to patient, it 
is important that the patient receives a uniform dose of the drug throughout the shelf 
life of the product. 
The International Conference on Harmonization (ICH) guidelines titled 
“Stability testing of new drug substances and products- Q1A (R2)” describes the 
stability test requirements for drug registration applications in the United States, 
European Union and Japan. 
 As per in-vitro release formulation F11 was found to be desirable than other 
formulations. Hence it was chosen for stability studies. The tablets were packed and 
kept for 3 months at different temperature 25oC / 60%RH, 30oC / 65%RH, 40oC / 75% 
RH in a stability chamber (Osworld, Mumbai). At the interval of 1 month tablets were 
withdrawn and evaluated for physical properties like thickness, hardness, diameter, 
friability, weight variation, buoyancy studies and content uniformity. In-vitro drug 
release is also carried out.  
6.5 Kinetic Analysis of In–Vitro Release Rates of Controlled Release Tablets of   
Atorvastatin80,82 
 The results of in-vitro release profile obtained for all the formulations were 
plotted in modes of data treatment as follows:- 
1. Zero – order kinetic model – Cumulative % drug released versus time. 
2. First – order kinetic model – Log cumulative % drug remaining versus time. 
3. Higuchi’s model – Cumulative % drug released versus square root of time. 
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4. Korsmeyer equation / Peppa’s model – Log cumulative % drug released 
versus log time. 
1.  Zero order kinetics: 
 Zero order release would be predicted by the following equation:- 
At = A0 – K0t 
Where, 
   At  =  Drug release at time ‘t’. 
   A0  = Initial drug concentration 
   K0  = Zero – order rate constant (hr-1). 
When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys Zero – order release kinetics, with a slope equal to K0. 
2.  First Order Kinetics: 
 First – order release would be predicted by the following equation:-   
Log C = log C0 – Kt / 2.303 
Where, 
C = Amount of drug remained at time‘t’. 
    C0 = Initial amount of drug. 
K = First – order rate constant (hr-1). 
 When the data is plotted as log cumulative percent drug remaining versus time 
yields a straight line, indicating that the release follow first order kinetics.  The 
constant ‘K’ can be obtained by multiplying 2.303 with the slope values. 
3.  Higuchi’s model: 
 Drug release from the matrix devices by diffusion has been described by 
following Higuchi’s classical diffusion equation. 
Q = [Dε / τ (2 A - εCs) Cst]1/2 
Where, 
    Q = Amount of drug released at time‘t’. 
    D = Diffusion coefficient of the drug in the matrix. 
    A = Total amount of drug in unit volume of matrix. 
    Cs = the solubility of the drug in the matrix. 
                                            τ = Porosity of the matrix. 
      ε = Tortuosity. 
         t = Time (hrs) at which ‘q’ amount of drug is released. 
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Above equation may be simplified if one assumes that ‘D’, ‘Cs’, and ‘A’, are 
constant.  Then equation becomes: 
                                                   Q = Kt1/2  
 When the data is plotted according to equation i.e. cumulative drug release 
versus square root of time yields a straight line, indicating that the drug was released 
by diffusion mechanism.  The slope is equal to ‘K’ . 
4.  Korsmeyer equation / Peppa’s model:84 
 To study the mechanism of drug release from the sustained – release matrix 
tablets of Zidovudine, the release data were also fitted to the well – known 
exponential equation (Korsmeyer equation / peppa’s  law equation), which is often 
used to describe the drug release behavior from polymeric systems. 
Mt / Ma = Ktn 
Where, 
 Mt / Ma = the fraction of drug released at time ‘t’. 
         K  = Constant incorporating the structural and geometrical   
   characteristics of the drug / polymer system. 
          n  = Diffusion exponent related to the mechanism of the release. 
 Above equation can be simplified by applying log on both sides, 
And we get: 
                                                Log Mt / Ma = Log K + n Log t 
 When the data is plotted as log of drug released versus log time, yields a 
straight line with a slope equal to ‘n’ and the ‘K’ can be obtained from y – intercept.  
For Fickian release ‘n’ = 0.5 while for anomalous (non – Fickian) transport ‘n’ ranges 
between 0.5 and 1.0.  The result of in-vitro drug release study of all the formulation as 
shown below. 
Table:11 Mechanism of Drug Release as per Korsmeyer Equation/Peppa’s 
Model 
S. No. n Value Drug release 
1. 0.45 Fickian release 
2. 0.45 <n <0.89 Non – Fickian release 
3. n> 0.89 Class II transport 
 
TABLE:8 COMPOSITION OF SUSTAINED RELEASE TABLET OF ATORVASTATIN CALCIUM  (in mg) 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Atorvastatin Calcium  
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
 
21.64 
HPMC 15,000cps  
15 
 
15 
 
15 
 
30 
 
30 
 
30 
 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
HPMC 100,000 cps  
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
15 
 
15 
 
22.5 
 
22.5 
 
30 
 
30 
Sodium bicarbonate  
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
 
22.5 
Avicel PH102  
7.5 
 
15 
 
22.5 
 
7.5 
 
15 
 
22.5 
 
7.5 
 
15 
 
15 
 
22.5 
 
15 
 
22.5 
Lactose DC 81.11 73.61 66.11 66.11 58.61 51.11 81.11 73.61 66.11 58.61 58.61 51.11 
Magnesium stearate  
0.75 
 
0.75 
 
0.75 
 
0.75 
 
0.75 
 
0.75 
 
0.75 
 
0.75 
 
0.75 
 
0.75 
 
 
0.75 
 
0.75 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Total Weight  
150 
 
150 
 
150 
 
150 
 
150 
 
150 
 
150 
 
150 
 
150 
 
 
150 
 
150 
 
150 
*20mg of Atorvastatin is equivalent to 21.64mg of Atorvastatin calcium   
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             8. RESULTS AND DISCUSSION 
 The present study was undertaken to formulate Atorvastatin calcium floating 
tablets. Controlled release dosage forms deliver the drug at a slow release rate over an 
extended period of time. The drug Atorvastatin calcium is formulated as a floating 
tablet due to its rapid absorption in acidic pH, high intestinal clearance and maintains 
required drug concentration in blood. 
 The tablets prepared in the present study by direct compression technique have 
advantages over those prepared by wet granulation in terms of time and energy 
consumption, thus making it possible to formulate tablets at a lower cost because of 
their flexibility, hydrophilic polymer matrix systems are widely used in oral 
controlled drug delivery.  
  The study involved pre-formulation of drugs and granules, formulation and 
processing development along with evaluation of the tablets. 
 
 8.1 PRE-FORMULATION STUDY OF DRUG: 
• The Atorvastatin calcium was subjected to drug-excipients compatibility 
study with excipients like hydroxyl propyl methyl cellulose, avicel PH102, 
sodium bicarbonate, anhydrous lactose, talc and magnesium stearate. The 
mixtures shown to have no colour change. 
• Good flow of powders / granules is essential in tableting, because the 
compressibility & flow properties of the drugs likely to influence the 
compression process in the preparation of tablets. In view of this the 
formulation were prepared by direct compression technique to improve the 
flow as well as compressability. 
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8.2 Characterization of Drug 
8.2.1 UV- Spectrum Analysis of Drug 
Atorvastatin drug solution in pH 1.2 was scanned using UV-Spectrophotometer 
between the range 200-400nm. which showed the maximum absorbance at 246nm. 
Figure 2: UV spectrum of Atorvastatin calcium 
 
Figure 3: UV spectrum peak value of Atorvastatin calcium 
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 8.2.2 INFRA RED SPECTROSCOPIC STUDIES: 
 
 By using FT IR technique, Atorvastatin calcium and polymers like hydroxyl 
propyl methyl cellulose, Avicel PH102, were identified by the frequency of the 
obtained peaks. 
 The interpretation of the infra red spectrum of the drug and polymers are as 
follows. 
 
 
Table:12 IR spectra of pure Atorvastatin calcium: 
Frequency ( cm-1) Groups assigned 
3400.62 O - H stretching (carboxyl) 
3058.24 Aromatic C - H stretching 
2959.87 Aliphatic C - H stretching 
1660.77 C = O stretching (carboxyl) 
1432.19 C - H bending 
1311.64 C – O stretching 
749.37 C – H out of plane bending 
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Table:13 IR spectra of HPMC K100M: 
Frequency ( cm-1 ) Groups assigned 
3469.09 O-H stretching (alcohol) 
2930.93 C-H stretching ( alkane) 
1462.09 C-H bending (alkane) 
1121.64 C-O stretching (alcohol) 
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Table:14 IR spectra of Avicel PH102: 
Frequency ( cm-1 ) Groups assigned 
3393.86 O-H stretching 
2900.07 Aliphatic C-H stretching 
1370.47 Aldehydic C-H bending 
1113.93 C-O stretching (20 alcohol) 
1060.88 C-O stretching (10 alcohol) 
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Table:15 IR spectra of Atorvastatin calcium + Avicel PH102: 
Frequency ( cm-1 ) Groups assigned 
3400.62 O-H stretching (alcohol) 
3062.10 Aromatic C-H stretching 
2955.04 Aliphatic C-H stretching 
1659.80 C = O stretching 
1227.73 C-O stretching 
748.81 C- H out of plane bending 
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Table:16 IR spectra of Atorvastatin calcium + HPMC K100M: 
Frequency ( cm-1 ) Groups assigned 
3467.16 O-H stretching (alcohol) 
3059.20 Aromatic C-H stretching 
1664.62 C = O stretching 
1224.84 C-O stretching 
750.33 C- H out of plane bending 
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Table:17 IR spectra of Atorvastatin calcium + HPMC + Avicel PH102: 
Frequency ( cm-1 ) Groups assigned 
3401.58 O-H stretching (alcohol) 
3060.17 Aromatic C-H stretching 
2956.01 Aliphatic C-H stretching 
1659.80 C = O stretching 
1225.80 C-O stretching 
748.41 C- H out of plane bending 
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IR Report: 
When FT IR Spectrum of Atorvastatin calcium (pure drug), excipients as 
polymer and disintegrant, there were no major changes in the position of the 
spectrum. It indicates the absence of physical and chemical interaction among the 
active components of Atorvastatin calcium and excipients. So the floating tablet of 
Atorvastatin calcium has no interaction with added excipients. 
 
8.2.3 DRUG – EXCIPIENTS COMPATIBILITY STUDIES:  
In this drug-excipient compatability study, by placing drug-excipient 
composition in different temperature were investigated. There was no change in 
physical appearance, color change and spectrum taken showing similar results. From 
this we concluded that there is no interaction between drug-excipients complex. 
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 8.3 EVALUATION OF POWDER BLEND: 
 The prepared blend of the formulations was evaluated for the parameters like 
angle of repose, bulk density, tap density, compressibility index and hausner’s ratio. 
   
• After granulation, angle of repose was improved. 
• Hausner ratio was found to be 1.2 (or) less than 1.2. 
• Carr's index was found to be in the range of 12 – 16. 
• All these values indicated that the granules have good flow property and 
hence the granulation process has improved the flow property. 
• For uniform tablet compression, good flow property is the major criteria.  
 
                    Table:18 Preformulation study data of the pure drug 
 
S.No Parameters Values obtained 
1. Angle of repose (θ) 22º57’  0.1332 
2. Bulk density (gm/ml) 0.3463 ±  0.007 
4. Tap density (gm/ml) 0.4544 ±  0.009 
5. Hausner’s ratio 1.312 ±  0.002 
6. Carr's index 23.55 ±  0.212 
  
      *Values mentioned are average of 3 determinations 
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Table:19 Physical Characteristics of controlled release powder blend 
Formulation code Angle of Repose (o) Bulk density Tap density Hausner ratio Carr's Index 
F1 20º14’ ± 0.4649 0.350 ±  0.011 0.410 ±  0.006 1.17 ±  0.003 14.63 ±  0.680 
F2 21º32’ ± 0.6133 0.351 ±  0.010 0.412 ±  0.003 1.17 ±  0.004 14.80 ±  0.521 
F3 21º17’ ± 0.6158 0.361 ±  0.010 0.430 ±  0.005 1.19 ±  0.002 16.20 ±  0.180 
F4 21º08’ ± 0.4255 0.371 ±  0.020 0.442 ±  0.003 1.19 ±  0.003 16.07 ±  0.101 
F5 22º15’ ± 0.7862 0.356 ±  0.011 0.421 ±  0.005 1.18 ±  0.002 15.43 ±  0.651 
F6 23º11’ ± 0.2606 0.370 ±  0.012 0.440 ±  0.004 1.18 ±  0.001 15.93 ±  0.181 
F7 21º08’ ± 0.6799 0.354 ±  0.012 0.425 ±  0.006 1.20 ±  0.002 16.76 ±  0.181 
F8 21º47’ ± 0.5718 0.350 ±  0.011 0.420 ±  0.002 1.20 ±  0.004 16.60 ±  0.701 
F9 22º18’ ± 0.2554 0.380 ±  0.012 0.450 ±  0.004 1.20 ±  0.002 15.52 ±  0.711 
F10 20º24’ ± 0.9529 0.361 ±  0.021 0.432 ±  0.002 1.19 ±  0.003 16.43 ±  0.621 
F11 20º08’ ± 0.4255 0.352 ±  0.011 0.423 ±  0.003 1.17 ±  0.001 14.23 ±  0.651 
F12 21º14’ ± 0.4649 0.360 ±  0.012 0.440 ±  0.004 1.18 ±  0.001 15.43 ±  0.521 
 *Values mentioned are average of 3 determinations 
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8.4 INVITRO RELEASE OF SUSTAINED RELEASE TABLET: 
   
 Table:20  Dissolution data of F1 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.85 9.25 9.25 
1 3.43 17.15 17.20 
2 5.04 25.20 25.29 
3 7.17 35.85 35.99 
4 9.17 45.85 46.04 
5 11.47 57.35 57.60 
6 13.11 65.55 65.86 
7 15.03 75.15 75.51 
8 16.42 82.10 82.51 
9 17.83 89.15 89.61 
10 19.24 96.20 96.69 
11 19.87 99.35 99.88 
 
 
 
 
 
Fig:4  Dissolution profile of F1 Formulation 
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Table:21  Dissolution data of F2 Formulation 
 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.58 7.90 7.90 
1 3.17 15.85 15.89 
2 5.30 26.50 26.58 
3 6.64 33.20 33.35 
4 9.31 46.55 46.73 
5 11.47 57.35 57.60 
6 13.11 65.55 65.86 
7 14.49 72.45 72.81 
8 15.89 79.45 79.85 
9 17.56 87.80 88.24 
10 18.44 92.20 92.68 
11 19.06 95.30 95.81 
12 19.43 97.15 97.67 
13 19.79 98.95 99.48 
 
 
 
 
Fig:5  Dissolution profile of F2 Formulation 
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Table:22 Dissolution data of F3 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.32 6.60 6.60 
1 2.91 14.55 14.58 
2 4.24 21.20 21.28 
3 6.11 30.55 30.66 
4 7.72 38.60 38.76 
5 9.34 46.70 46.91 
6 10.97 54.85 55.10 
7 12.87 64.35 64.65 
8 14.26 71.30 71.65 
9 15.92 79.60 79.99 
10 17.05 85.25 85.69 
11 18.20 91.00 91.47 
12 19.08 95.40 95.90 
13 19.45 97.25 97.78 
14 19.81 99.05 99.59 
15 19.90 99.50 100.05 
 
 
 
 
Fig:6 Dissolution profile of F3 Formulation 
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Table:23 Dissolution data of F4 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.05 5.25 5.25 
1 2.91 14.55 14.57 
2 4.23 21.15 21.23 
3 6.11 30.55 30.66 
4 7.72 38.60 38.76 
5 9.34 46.70 46.91 
6 10.97 54.85 55.10 
7 12.87 64.35 64.65 
8 14.52 72.60 72.95 
9 15.91 79.55 79.95 
10 17.05 85.25 85.69 
11 18.20 91.00 91.47 
12 19.08 95.40 95.90 
13 19.45 97.25 97.78 
14 19.81 99.05 99.59 
 
 
 
 
Fig:7 Dissolution profile of F4 Formulation 
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Table:24  Dissolution data of F5 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.58 7.90 7.90 
1 2.91 14.55 14.59 
2 4.51 22.55 22.63 
3 5.84 29.20 29.32 
4 7.19 35.95 36.11 
5 8.81 44.05 44.24 
6 10.17 50.85 51.09 
7 11.28 56.40 56.68 
8 12.93 64.65 64.96 
9 14.31 71.55 71.90 
10 15.97 79.85 80.24 
11 17.11 85.55 85.99 
12 17.99 89.95 90.42 
13 18.61 93.05 93.54 
14 19.23 96.15 96.66 
15 19.60 98.00 98.53 
16 19.71 98.55 99.09 
 
 
 
Fig:8 Dissolution profile of F5 Formulation 
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Table:25 Dissolution data of F6 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.32 6.60 6.60 
1 2.11 10.55 10.58 
2 3.44 17.20 17.25 
3 4.78 23.90 13.99 
4 6.65 33.25 33.38 
5 7.73 38.65 38.83 
6 8.83 44.15 44.36 
7 10.20 51.00 51.24 
8 11.57 57.85 58.13 
9 13.21 66.05 66.37 
10 14.86 74.30 74.66 
11 16.26 81.30 81.71 
12 17.40 87.00 87.45 
13 18.28 91.40 91.88 
14 18.90 94.50 95.01 
15 19.27 96.35 96.87 
16 19.63 98.15 98.68 
17 19.73 98.65 99.19 
 
 
 
 
Fig:9 Dissolution profile of F6 Formulation 
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Table:26 Dissolution data of F7 Formulation: 
 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.05 5.25 5.25 
1 2.11 10.55 10.57 
2 3.44 17.20 17.25 
3 4.78 23.90 23.99 
4 6.38 31.90 32.03 
5 7.73 38.65 38.82 
6 9.09 45.45 45.66 
7 9.93 49.65 49.90 
8 11.30 56.50 56.77 
9 12.68 63.40 63.71 
10 14.06 70.30 70.65 
11 15.19 75.95 76.34 
12 15.80 79.00 79.42 
13 16.67 83.35 83.78 
14 18.35 91.75 92.21 
15 18.97 94.85 95.35 
16 19.59 97.95 98.47 
17 19.69 98.45 98.99 
 
 
 
 
 
Fig:10 Dissolution profile of F7 Formulation 
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Table:27 Dissolution data of F8 Formulation 
 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.32 6.60 6.60 
1 2.11 10.55 10.58 
2 4.24 21.20 21.25 
3 5.31 26.55 26.66 
4 6.39 31.95 32.09 
5 7.74 38.70 38.87 
6 8.84 44.20 44.41 
7 9.94 49.70 49.94 
8 11.05 55.25 55.52 
9 12.42 62.10 62.40 
10 13.28 66.40 66.74 
11 13.87 69.35 69.71 
12 14.74 73.70 74.08 
13 15.87 79.35 79.75 
14 17.01 85.05 85.49 
15 17.89 89.45 89.92 
16 18.77 93.85 94.34 
17 19.13 95.65 96.17 
18 19.50 97.50 98.03 
19 19.86 99.30 99.84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig:11 Dissolution profile of F8 Formulation 
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Table:28  Dissolution data of F9 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 1.05 5.25 5.25 
1 1.85 9.25 9.27 
2 3.44 17.20 17.25 
3 4.78 23.90 23.99 
4 6.12 30.60 30.73 
5 7.47 37.35 37.52 
6 8.56 42.80 43.00 
7 9.66 48.30 48.53 
8 10.50 52.50 52.76 
9 11.35 56.75 57.04 
10 12.20 61.00 61.31 
11 13.32 66.60 66.90 
12 14.18 70.90 71.27 
13 15.31 76.55 76.94 
14 16.44 82.20 82.62 
15 17.59 87.95 88.41 
16 17.94 89.70 90.18 
17 18.56 92.80 93.29 
18 19.19 95.95 96.47 
19 19.55 97.75 98.28 
20 19.91 99.55 100.09 
 
 
 
Fig:12 Dissolution profile of F9 Formulation 
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Table:29 Dissolution data of F10 Formulation: 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 0.79 3.95 3.95 
1 1.58 7.90 7.92 
2 2.91 14.55 14.59 
3 4.24 21.20 21.28 
4 5.58 27.90 28.01 
5 6.93 34.65 34.80 
6 8.02 40.10 40.29 
7 8.85 44.25 44.47 
8 9.96 49.80 50.04 
9 11.06 55.30 55.07 
10 12.17 60.85 61.15 
11 13.03 65.15 65.48 
12 14.15 70.75 71.11 
13 15.02 75.10 75.49 
14 15.89 79.45 79.86 
15 17.03 85.15 85.59 
16 18.17 90.85 91.32 
17 18.53 92.65 93.15 
18 18.89 94.45 94.96 
19 19.25 96.25 96.77 
20 19.61 98.05 98.58 
21 19.71 98.55 99.09 
 
 
 
 
 
Fig:13 Dissolution profile of F10 Formulation 
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Table:30  Dissolution data of F11 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 0.79 3.95 3.95 
1 1.58 7.90 7.92 
2 2.91 14.55 14.59 
3 3.98 19.90 19.98 
4 5.05 25.25 25.30 
5 6.13 30.65 30.79 
6 7.22 36.10 36.27 
7 7.78 38.90 39.10 
8 8.62 43.10 43.30 
9 9.19 45.95 48.18 
10 10.29 51.45 51.70 
11 10.87 54.35 54.63 
12 11.72 58.60 58.90 
13 12.38 61.90 62.22 
14 13.43 67.15 67.49 
15 14.03 70.15 70.52 
16 14.63 73.15 73.53 
17 15.50 77.50 77.90 
18 16.63 83.15 83.58 
19 17.25 86.25 86.71 
20 18.13 90.65 91.12 
21 18.75 93.75 94.25 
22 19.11 95.55 96.07 
23 19.47 97.35 97.88 
24 19.84 99.20 99.74 
 
 
 
 
Fig:14 Dissolution profile of F11 Formulation 
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Table:31 Dissolution data of F12 Formulation 
Time(hrs) Amount of drug release 
 
% Drug release 
Cumulative % 
drug release 
0.5 0.79 3.95 3.97 
1 1.32 6.60 6.62 
2 2.38 11.90 11.93 
3 3.18 15.90 15.96 
4 4.25 21.25 21.33 
5 5.33 26.65 26.76 
6 6.15 30.75 30.89 
7 7.24 36.20 36.37 
8 8.07 40.35 40.55 
9 9.16 45.80 46.02 
10 10.00 50.00 50.25 
11 10.84 54.20 54.47 
12 11.96 59.80 60.11 
13 13.07 65.35 65.68 
14 13.93 69.65 70.01 
15 14.80 74.00 74.38 
16 15.40 77.00 77.41 
17 15.75 78.75 79.18 
18 15.83 79.15 79.60 
19 16.18 80.90 81.34 
20 16.79 83.95 84.41 
21 17.40 87.00 87.50 
22 17.75 88.75 89.28 
23 18.11 90.55 91.07 
24 18.47 92.35 92.86 
 
 
 
Fig:15 Dissolution profile of F12 Formulation 
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Table:32 COMPARATIVE DISSOLUTION STUDY OF ALL THE BATCHES 
 
S.No 
 
Formulations 
Time (hrs) of 
drug release 
 
%Drug   
release 
 
Cumulative % drug 
release 
1 F1 11 99.35 99.88 
2 F2 13 98.95 99.48 
3 F3 15 99.5 100.05 
4 F4 14 99.05 99.59 
5 F5 16 98.55 99.09 
6 F6 17 98.65 99.19 
7 F7 17 98.45 98.99 
8 F8 19 99.3 99.84 
9 F9 20 99.55 100.09 
10 F10 21 98.55 99.09 
11 F11 24 99.20 99.74 
12 F12 24 92.35 92.86 
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Dissolution profile for all formulations F1-F12: 
 
 
 
 
Fig:16 Comparative dissolution profile of all formulations F1-F12 
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DISCUSSION ON DISSOLUTION PROFILE OF SUSTAINED RELEASE 
TABLET: 
 In this formulation, initially we tried with poly ethylene oxide, which had 
good buoyancy property but no proper invitro drug release due to more viscosity in 
the gastric fluid, leads to a poor drug release. Then we used HPMC K4M instead of 
poly ethylene oxide, the tablet was completely disintegrated in gastric medium. So we 
aimed to use the higher grades of HPMC (HPMC K15M) to improve the stability of 
tablet.  
 In F1, F2, F3 formulations, HPMC K15M was used in concentration of 10% 
and binder Avicel PH102 used in respective formulations as 5%, 10%, 15%. The 
releases of above formulations were found to be in higher side. So, we planned to 
increase the concentration of HPMC K15M to improve the sustain release property. 
In F4,F5,F6 formulations, HPMC K15M was used in concentration of 30% and 
binder Avicel PH102 used in respective formulations as 5%, 10%, 15%. The releases 
of above formulations were sustained but it is not upto 24 h what we expected.  So, 
we planned to increase the viscosity of HPMC K15M to improve the sustain release 
property further. 
Again we tried the formulation with higher grade of HPMC(HPMC K100M) 
having higher viscosity in different concentration as 10%, 15%, 20% and Avicel 
PH102 used in concentration of 5%, 10%, 15% to sustain the drug release. 
 In F7, F8 formulations, HPMC K100M of 10% and Avicel PH102 of 5%, 10% 
were included and the release was extended upto 17 h and 19 h respectively. In F9,F10 
formulations, HPMC K100M of 15% and Avicel PH102 of 10 and 15% were 
included, among that formulation F10 showed a dissolution profile upto 21h. 
 Finally F11, F 12 formulations consisted of HPMC K100M 20% and avicel 
PH102 of 10%, 15% in respective formulation. The formulations F11, F 12 was 
achieved 24 h dissolution profile due to increase in polymer concentration, but in F12 
100% of drug was not released in 24 h. Hence, the formulation F11 is the optimized 
one, which had showed the invitro release pattern of sustained release of Atorvastatin 
calcium was found to be satisfactory as per USP limit. 
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8.5 EVALUATION OF TABLETS  
 
(a) Thickness and Diameter: 
 The thickness and diameter were found in the range of 2.78 ± 0.04 to 2.84 
± 0.03 and 7.2 ±  0.018 to 7.9 ±  0.028 respectively. 
 
Table:33 Thickness and Diameter data of the tablets 
 
Formulation 
Code 
Thickness (mm) ±  S.D Diameter (mm) ±  S.D 
F1 2.83 ± 0.013 7.1 ±  0.114 
F2 2.79± 0.016 7.0 ±  0.89 
F3 2.87±  0.016 7.2 ±  0.018 
F4 2.86 ±  0.018 7.1 ±  0.010 
F5 2.73 ±  0.013 7.2 ±  0.018 
F6 2.81 ±  0.013 7.0 ±  0.014 
F7 2.88 ±  0.011 7.2 ±  0.032 
F8 2.87 ±  0.016 7.2 ±  0.017 
F9 2.9 ±  0.019 7.1 ±  0.016 
F10 2.87 ±  0.013 7.0 ±  0.028 
F11 2.83 ±  0.015 7.1 ±  0.01 
F12 2.84 ±  0.016 7.0 ±  0.028 
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b) Weight Variation, Hardness and Friability: 
 Depending upon the ingredients of different formulations, the weight of tablet 
was fixed. In each formulation, weight variation was within the I.P limit. Mostly, the 
variation was within  ±  5%. The hardness of the different formulations ranged from 
5-7 kg / cm2. All the formulations exhibited less than 1% friability.  
 
Table:34 Hardness, weight variation and Friability data of the tablets 
  
Formulation 
Code 
weight variation 
(mg) ± S.D 
Hardness 
(Kg/cm2) ±  S.D 
Friability (%) ±  
S.D 
F1 152 ±  1.09 5.8 ±  0.244 0.31 ±  0.002 
F2 151±  1.14 6.4 ±  0.251 0.26 ±  0.004 
F3 150±  1.14 6.3 ± 0.244 0.34 ±  0.003 
F4 152 ±  0.41 6.7 ± 0.244 0.36 ±  0.003 
F5 151 ±  1.30 6.5 ±  0.048 0.34 ±   0.014 
F6 151 ±  1.51 6.5 ±  0.447 0.32 ±  0.009 
F7 152 ±  1.48 6.3 ±  0.244 0.33 ±  0.014 
F8 151 ±  0.83 6.2 ±  0.244 0.30 ±  0.009 
F9 150 ±  1.22 6 ± 0.316 0.33 ±  0.007 
F10 152 ±  1.30 6.2 ±  0.244 0.39 ±  0.011 
F11 150 ±  1.14 6.5 ±  0.447 0.33 ±   0.010 
F12 151±  1.51 6.8 ±  0.244 0.32 ±  0.006 
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c) Content uniformity : 
 The results for content uniformity are presented in table 35. The results were 
found to be within the limits (98 to 99.5%). It shows that the drug was uniformly 
distributed throughout the tablets.  
 
Table:35 Content uniformity data of the tablets 
 
Formulation Code 
Content uniformity in 
percentage ± S.D 
F1 99.18 ±  0.11 
F2 99.28 ±  0.43 
F3 98.12 ±  1.00 
F4 99.19 ±  1.00 
F5 98.06 ±  0.03 
F6 99.18 ±  0.43 
F7 99.16 ±  0.10 
F8 98.23 ±  0.20 
F9 98.95 ±  0.20 
F10 99.20 ±  0.11 
F11 98.26 ±  0.17 
F12 99.08 ±  0.43 
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d) Buoyancy Studies: 
 The result of buoyancy studies of the formulations were shown in the table:36. 
It is one of the major property of the floating tablet. In this study, the result had 
showed all the formulations buoyant for more than 24 h. It shows that all the 
formulations float for a day and release the drug. 
 
Table:36 Buoyancy Studies of tablets 
Formulation Code Buoyancy Lag Time(in secs) Buoyancy Time(in hrs) 
F1 32 25 
F2 33 25 
F3 35 26 
F4 30 26 
F5 28 26 
F6 22 26 
F7 35 28 
F8 22 28 
F9 20 28 
F10 21 28 
F11 25 28 
F12 23 30 
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8.6 STABILITY STUDIES: 
 
 The optimized F11 formulation was subjected to accelerated stability 
conditions for 3 months at 25oC/60% RH, 30oC / 75% RH, 40oC / 75% RH in a 
stability chamber (Osworld, Mumbai), at the interval of 1 month tablets were taken 
and evaluated for various parameters like thickness, diameter, weight variation, 
hardness, content uniformity and dissolution. The tablets had showed slight variation 
in the tested parameters and the results were within the limits. 
 
 
  Table:37 Comparison of physical parameters for optimized formulation F11 
  
S.No. Parameters F11 
25oC/60%RH 
At the end of 
1st month 
At the end of 
2nd month 
At the end of 
3rd  month 
1. Thickness 
(mm) 
2.82 ±  0.013 2.82 ±  0.016 2.83 ± 0.014 2.84 ± 0.019 
2. Diameter 
(mm) 
7.9 ± 0.018 7.7± 0.012 7.9 ± 0.015 7.8 ± 0.017 
3. Hardness 
(kg/cm2) 
6.8 ± 0.244 6.3± 0.316 6.3 ± 0.221 6.2 ± 0.115 
4. Friability 
(%) 
0.36 ± 0.009 0.38 ± 0.007 0.40 ± 0.009 0.41 ± 0.008 
5. Weight 
Variation 
(mg) 
151 ± 0.815 150 ± 0.525 150 ± 0.265 150 ± 0.151 
6. Content 
Uniformity 
99.25 ± 0.20 99.12 ± 0.110 99.16 ± 0.112 99.16 ± 0.110 
 
9 F11: Optimized formulation 
9 Formulation batch F11 kept for stability study at temperature (25oC/60%RH). 
 
 
RESULTS AND DISCUSSION 
 
 
Dept. of Pharmaceutics, K.M.College of Pharmacy, Madurai               98 
 
Table:38 Dissolution data of F11 batch at 25oC / 60% RH 
 
 
Time(hrs) 
Cumulative % Drug Release 
At the end of 1st 
month 
At the end of 2nd 
month 
At the end of 3rd  
month 
0.5 5.25 5.25 5.25 
1 9.28 9.27 10.57 
2 15.95 14.6 17.25 
3 21.34 21.28 21.34 
4 28.26 28.06 28.06 
5 33.5 34.8 34.85 
6 38.98 38.99 41.64 
7 45.81 44.56 47.18 
8 51.35 51.34 51.41 
9 56.93 55.58 55.63 
10 60.71 61.21 61.27 
11 65.48 65.48 65.53 
12 70.66 69.81 69.86 
13 75.49 74.18 72.88 
14 79.86 79.86 77.25 
15 82.94 82.89 82.97 
16 86.05 86 87.35 
17 89.12 89.12 89.13 
18 90.94 90.89 90.94 
19 92.75 92.7 92.75 
20 94.56 94.51 94.56 
21 96.37 96.32 96.37 
22 98.18 96.83 96.88 
23 98.69 98.63 98.68 
24 99.24 99.19 99.17 
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Fig:17 Dissolution profile of F11 batch at 25oC/60%RH 
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Table:39 Comparison of physical parameters for optimized formulation F11 
 
S.No. Parameters F11 
30oC/65%RH 
At the end of 
1st month 
At the end of 
2nd month 
At the end of 
3rd  month 
1. Thickness 
(mm) 
2.81 ±  0.018 2.81±  0.014 2.80 ± 0.012 2.82 ± 0.014 
2. Diameter 
(mm) 
7.8±  0.016 7.6± 0.012 7.5 ± 0.015 7.6 ± 0.017 
3. Hardness 
(kg/cm2) 
6.6 ±  0.244 6.5± 0.048 6.5 ± 0.251 6.4 ± 0.316 
4. Friability 
(%) 
0.35 ±  0.017 0.37 ± 0.027 0.39 ± 0.007 0.40 ± 0.026 
5. Weight 
Variation 
(mg) 
150 ±  0.742 150 ± 0.453 150 ± 0.342 149 ± 0.251 
6. Content 
Uniformity 
99.27 ± 0.037 99.22 ± 0.084 99.12 ± 0.114 99.16  0.078 
 
9 F11: Optimized formulation 
9 Formulation batch F11 kept for stability study at temperature (30oC/65%RH). 
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Table:40 Dissolution data of F11 batch at 30oC / 65% RH 
 
Time(hrs) 
Cumulative % Drug Release 
At the end of 1st 
month 
At the end of 2nd 
month 
At the end of 3rd  
month 
0.5 5.29 5.25 3.95 
1 9.27 9.27 7.92 
2 14.6 15.95 14.59 
3 19.98 22.63 21.28 
4 26.71 28.08 26.73 
5 32.14 34.86 32.14 
6 38.92 41.64 38.92 
7 44.46 48.48 45.76 
8 49.99 52.71 50.02 
9 55.57 58.29 55.57 
10 59.85 63.92 61.15 
11 64.13 68.2 65.43 
12 68.45 72.57 69.76 
13 72.77 75.6 72.78 
14 75.08 79.96 77.15 
15 80.16 84.39 80.22 
16 84.59 87.46 84.59 
17 87.66 89.23 87.71 
18 90.78 92.39 89.48 
19 92.6 94.16 91.29 
20 94.41 95.97 93.12 
21 96.22 96.48 94.91 
22 98.03 98.33 95.34 
23 98.59 98.84 97.22 
24 99.09 99.04 97.73 
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Fig:18 Dissolution profile of F11 batch at 30oC/65%RH 
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Table:41 Comparison of physical parameters for optimized formulation F11 
 
S.No. Parameters F11 
40oC/75%RH 
At the end of 
1st month 
At the end of 
2nd month 
At the end of 
3rd  month 
1. Thickness 
(mm) 
2.81 ±  0.016 2.80±  0.012 2.81 ± 0.012 2.80 ± 0.014 
2. Diameter 
(mm) 
7.7±  0.019 7.8± 0.014 7.7 ± 0.01 7.5 ± 0.018 
 
3. 
Hardness 
(kg/cm2) 
6.7 ±  0.226 6.6± 0.146 6.5 ± 0.251 6.5 ± 0.244 
4. Friability 
(%) 
0.39 ±  0.028 0.40 ± 0.017 0.40 ± 0.009 0.42 ± 0.012 
5. Weight 
Variation 
(mg) 
151 ±  0.125 150 ± 0.254 150 ± 0.162 149 ± 0.156 
6. Content 
Uniformity 
99.28 ± 0.036 99.15 ± 0.087 99.09 ± 0.112 99.03 ± 0.110 
 
9 F11: Optimized formulation 
9 Formulation batch F10 kept for stability study at temperature (40oC/75%RH). 
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Table:42 Dissolution data of F11 batch at 40oC / 75% RH 
 
Time(hrs) 
Cumulative % Drug Release 
At the end of 1st 
month 
At the end of 2nd 
month 
At the end of 3rd  
month 
0.5 5.29 5.25 5.25 
1 7.92 10.57 10.58 
2 14.59 17.25 17.25 
3 19.98 23.99 22.64 
4 26.06 29.38 29.42 
5 33.5 34.86 36.16 
6 38.93 40.34 41.65 
7 44.56 45.87 47.18 
8 49.99 52.7 52.76 
9 55.57 56.99 56.99 
10 59.85 62.56 61.26 
11 64.13 68.24 65.58 
12 69.75 72.57 69.91 
13 72.78 75.6 75.58 
14 77.15 79.96 79.96 
15 80.22 84.39 83.04 
16 84.59 87.46 84.55 
17 87.71 89.23 86.56 
18 90.78 91.04 86.67 
19 92.6 92.85 90.12 
20 93.11 93.31 91.94 
21 94.91 95.11 93.75 
22 96.72 96.97 95.56 
23 98.53 97.43 96.07 
24 99.09 97.98 97.83 
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Fig:19 Dissolution profile of F11 batch at 40oC/75%RH 
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8.6 PHENOMENON OF DRUG RELEASE 
 
 The formulations was subjected to graphical treatments to assess the kinetics of 
drug release. 
 
 Release was approaching Zero order. 
 
Zero order Equation: 
 The results data was fitted into the Zero order equation. 
 Q = K0t 
 Q = The amount of drug released at time t 
 K0 = Release rate 
 
First order Equation: 
 The results data was fitted into the first order equation. 
 Log C = Log C0 –  k t / 2.303 
 C0 – is the initial concentration of drug 
 K – is the first order constant 
 t  - is the time. 
 
Higuchi Plot: 
 The graph was plotted between cumulative % release and square root of time. The 
regression value of F11 was 0.971. This indicates, that diffusion is one of the mechanism 
of drug release. 
 
Peppas  Plot: 
 The graph was plotted between log cumulative % of release and log time. The 
slope (n) value of F11 was 0.789. This indicates, swelling mediated diffusion is the 
mechanism of drug release. 
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ANALYSIS OF RELEASE DATA: 
In kinectis data, Figure 20, 21, 22, 23 had showed the correlation coefficient of 
different kinetic models for Atorvastatin calcium optimized (F11) formulation. Higuchi 
plots were found to be of highest linearity with correlation coefficient greater than that of 
the zero order kinetics and corresponded to that of the first order kinetics indicating that 
the drug release mechanism from the tablets by diffusion method. Studies revealed that 
the release of Atorvastatin calcium was found to be very close to zero-order kinetics in 
simulated gastric fluid, indicating that the concentration was nearly independent of drug 
release. Moreover, in-vitro release of Atorvastatin calcium was best explained by 
Korsmeyer-Peppas equation also indicated a good linearity. The release exponent ‘n’ was 
0.789, which indicates anomalous diffusion.  
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A) Zero-Order Kinetics Plot: 
 
ZERO ORDER PLOT 
 
 
 
Fig:20 Zero-order release profile of optimized ( F11) Formulation 
 
 
 
 
 
 
 
 
Zero order release kinetics 
R2 
0.990 
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B) First-Order Kinetics Plot: 
FIRST ORDER PLOT 
 
 
 
     Fig:21 First-order release profile of optimized ( F11) Formulation 
 
First order release kinetics 
R2 
0.929 
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C) Higuchi Plot: 
HIGUCHI PLOT 
 
 
 
Fig:22 Higuchi release profile of optimized ( F11) Formulation 
 
 
 
 
 
 
 
 
 
 
Higuchi release kinetics 
R2 
0.971 
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D)Korsemeyer – Peppas model  Kinetics Plot: 
PEPPAS PLOT 
 
 
 
 
         Fig:23 Korsemeyer – Peppas release profile of optimized ( F11) Formulation 
 
 
 
 
 
Korsemeyer – Peppas model release kinetics 
n 
0.789 
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9.  CONCLUSION 
Atorvastatin calcium is an inhibitor of 3-hydroxy-3-methylglutaryl-
coenzymeA (HMG-CoA) reductase. This enzyme catalyzes the conversion of 
HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol 
biosynthesis. 
Gastro Retentive Drug Delivery System of Atorvastatin calcium could 
be successfully formulated by direct compression technique, using different 
viscosity grades of Hydroxy Propyl Methyl Cellulose, Avicel PH102 was used 
as binder, sodium bicarbonate as gas generating agent, talc as glidant, 
magnesium stearate as lubricant and lactose as diluent. The optimized tablet 
formulation had showed 99.74% of drug release in 24 h. Therefore the 
optimized formulation containing HPMC K100M with Avicel PH102 
sustained the drug release for a period of 24 h and remains buoyant throughout 
the studies. Among the different grades of HPMC, HPMC K100M showed the 
maximum retardation in drug release. 
 The invitro dissolution profile of drug release from the tablets 
followed zero order kinetics. From the higuchi plot of dissolution profile, we 
found that the drug was released by diffusion mechanism and from the peppas 
plot we concluded that the release mechanism was found to be non Fickian 
release. The optimized formulation undergoes stability study at 25◦C / 
60%RH, 30◦C / 65%RH, 40◦C / 75%RH. There was a slight change in physical 
characteristics, buoyancy study and dissolution study.  
 Finally, it was concluded that Gastro Retentive Drug Delivery System 
of Atorvastatin calcium prepared with higher viscosity grade HPMC K100M, 
which sustain the release of the drug in the GIT.  
It is a promising approach as it can able to release the required quantity 
of drug to the body, which results in minimizing the major side effect as 
rhabdomyolysis by minimizing the drug concentration in blood and also the 
entire dose was released in acidic medium, where atorvastatin having more 
absorption and ultimately leads to better patient therapy. 
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